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ABSTRACT OF DISSERTATION

MEANINGFUL MEASUREMENT MATTERS:
DEFINING POTENTIALLY INAPPROPRIATE MEDICATION USE
TO TARGET COGNITIVE OUTCOMES
Preventable and unintended consequences of medication use occur in more than
25% of ambulatory and hospitalized patients, and nearly half of long-term care patients.1
Unfortunately, many medications used to treat common health conditions in older adults
(such as anxiety, behavioral disturbances, incontinence, insomnia, depression, and pain)
have also been linked to cognitive impairment and decline. Recently, substantial efforts
to investigate medications and medication classes that may be associated with cognitive
impairment and decline in older adults have been undertaken. Unfortunately, studies
have used a wide variety of different tools to define “potentially inappropriate medication”
(PIM) use, and no published literature has consistently associated a particular
medication appropriateness tool with cognitive outcomes, leaving clinicians and patients
without a much-needed approach to deprescribing for preservation of cognitive function.
Given the national focus on prevention of cognitive decline, the vast pool of available
PIM measurement tools, and the variety of ways in which to consider exposure to PIMs,
there is a need to determine which tool (if any) identifies PIMs most strongly associated
with cognitive decline. Without widespread consensus as to what measure of PIM use is
the best to use when studying the aptitude of medications to cause cognitive decline,
clinicians will not have the tools they need to improve outcomes for their patients. As the
world awaits further developments that may one day produce an effective treatment (or
even cure) for the terrible brain-destroying disease of dementia, we can take steps today
to improve medication therapy that may dampen its horrific impact on the lives of older
adults and their loved ones.
In this work, we set out to examine the issue of measuring medication
appropriateness to target cognitive outcomes with the intent of informing future research
and clinical practice. While the gold-standard in evidence generation remains
randomized placebo-controlled clinical trials, we have seen that even the most rigorously
performed trials are not useful to generate evidence if there is not a consistent meaning
to "inappropriate medication." Groundwork must laid to provide crucial validation and
consensus to the measurement of medication appropriateness in light of cognition, and
then it must be applied to numerous prospective research endeavors in order to provide
a synthesized evidence-base for how medications should be managed to ensure
appropriate use in older adults wishing to preserve cognition.

In this first section, we have provided a historical context for the importance of
medication management, described the current state of affairs in the US and around the
world, and provided an overview of the available tools that have been used to measure
medication appropriateness with a perspective toward cognition.
Section two will utilize a number of these tools to estimate prevalence of potentially
inappropriate medication use in various populations of American older adults.
The next section will use various methodological techniques and data sources to
explore how some of these tools may or may not be associated with cognitive decline in
older adults. We will define both PIM use and cognitive decline in a variety of ways to
determine the effect varying definitions may have on new evidence generation.
Finally, we will explore how the findings provided in this work may be applied to
clinical practice, future research endeavors, and governmental policies.

KEYWORDS: dementia, potentially inappropriate medication, measurement validation,
cognitive decline, deprescribing
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1
1.1

INTRODUCTION

Changing Healthcare, Changing Priorities

The year is 1900, and the United States of America (US) had finally established
itself as a world power: successful agricultural ventures, transcontinental railroads,
and the world's largest steel production meant life in America was good.1 The
average US newborn could expect to live approximately 47 years, and the top
three causes of death were pneumonia, tuberculosis, and gastrointestinal
infections.2 Only one in twenty Americans were over the age of 65.
Medicine was rapidly adapting to the new "germ theory" of disease, and the
success of antibiotics and other public health interventions meant that by the mid20th century, life expectancy had risen nearly 20 years and the leading causes of
death shifted to chronic conditions.3 With this shift came the increasing importance
of medication therapy in lives of all Americans, but especially for older adults. As
studies of the causes of chronic diseases expanded more focus was drawn to
prevention of long-term consequences of chronic disease, including treatment of
such conditions as hypertension and hyperlipidemia.4 By the beginning of the 21st
century, one in six Americans was at least 65 years old, and multimorbidity had
become the normal state for older adults.5 In fact, 15% of adults aged 65 years
and older have four or more common chronic conditions.6
The changes in healthcare and its delivery over the last century have led to
a landscape in which heart disease and cancer have taken over as the leading
causes of death in America, and providers have needed to adapt into a more
specialty-driven model. Just as medical doctors branched out into specialized
subdivisions of internal medicine to treat specific diseases,7 so did pharmacists
begin to play a larger role in the clinical management of medications.8 While
medication management is important in all disease states for patients of all ages,
the burden of multimorbidity in older adults as well as biological changes leading
to pharmacokinetic and pharmacodynamic peculiarities makes managing their
multiple treatments especially important.
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1.2

Medication Management in Older Adults

The older adult population represents a unique challenge to optimization of
medication appropriateness. Although many in this population suffer from lifelimiting diseases, the course from diagnosis and initial medication therapy is
neither short nor linear. The vast variability in health status amongst older adults –
known as aged heterogeneity9 – creates a complex situation wherein healthcare
providers must take generalized guidelines and apply them to individuals who
range functionally from fit to frail. Thus, it becomes of essential importance for
healthcare providers to consider their patients’ desires and choices while medical
priorities continue to change. A survey of physicians found that some of the most
important barriers to optimizing medication use in older adults include “inadequate
guidelines, incomplete medical histories, lack of time, avoidance of negative
consequences, established beliefs in the benefits and harms of medication use
and others.”10
Evidence-based medicine dictates that healthcare providers should use
clinical practice guidelines (CPGs) to direct treatment regimens for all patients.
While multiple medication therapies can often be effective, and many CPGs
recommend them, many fail to consider the impact these guidelines can have on
older adults with multimorbidity. While appropriate use of multiple medications in
older adults is common and often beneficial, strict adherence to CPGs can result
in polypharmacy (the receipt of too many medications), which increases the
potential for adverse drug reactions (ADRs) and drug-drug interactions (DDIs).11
ADRs and DDIs can be especially troublesome because they can be difficult to
distinguish from other medical conditions, often resulting in the prescribing of more
medications to treat symptoms caused initially by a DDI or ADR. This phenomenon
is known as a “prescribing cascade”12 (see Figure 1.6.1).
Today, polypharmacy is so common that it was considered a priority
medication safety concern by the US government in 1990,13 and has been
consistently associated with numerous adverse health outcomes.14 As the tide
ebbs and flows, the field has come to realize that assessing medication
appropriateness is not as simple as merely counting the number of medications
2

one receives.15 Even in cases where significant polypharmacy is present,
investigators and clinical providers alike realize that there is more nuance to
appropriateness than ADRs and DDIs. In a recent systematic review with an expert
panel, clinicians identified 16 additional indicators that guide decisions into whether
polypharmacy is appropriate.16 Nearly all of these indicators revolve around
patient-specific factors that can transform an otherwise appropriate medication into
an inappropriate therapy. Another review found 138 different definitions for
polypharmacy, with 65 different studies defining polypharmacy as either ≥4 or ≥5
total medications.17 Other definitions consider varying extents of polypharmacy,
such as hyperpolypharmacy, or the use of ≥10 medications.
Despite its vast range of definitions, there is a general perception by
researchers, policymakers, and clinicians alike that polypharmacy is always
inappropriate.

While

many

studies

have

found

associations

between

polypharmacy and multiple health outcomes including mortality, ADEs, and
hospitalization,18–20 more recent publications have advocated shifting toward using
the term “appropriate polypharmacy” to encourage providers to focus on patientspecific context that may be more clinically relevant than a count of medications.15
These concerns have not gone unnoticed in the medical community.
Recognizing that specialized guidance may help ameliorate the problem of
complex treatment decisions in multimorbid older adults, researchers and
clinicians have undertaken to provide such recommendations. The "CRIteria to
assess appropriate Medication use among Elderly complex patients" (CRIME)
project provided recommendations for treating five common comorbidities in older
adults.21 These recommendations are based on taking a systematic approach to
ensuring optimal therapy, which can be broken down into 8 steps22 (Figure 1.6.2).
Further complicating prescribing decisions in older adults is the fact that often
medication effectiveness and safety are in conflict, as are costs and patient choice
(see Figure 1.6.3).
Governments throughout the world have begun to recognize this problem
and take action. A stellar example of proactive emphasis on this problem can be
found in Australia. The Australian government has been emphasizing the

3

importance of “quality use of medicines” since 1999, and most recently has
published recommendations for a national strategy to reduce PIM use in older
adults.23 Similarly, the European Union has taken steps to improve awareness and
research into both polypharmacy and PIM use with their Stimulating Innovation
Management of Polypharmacy and Adherence in THe ElderlY (SIMPATHY)
project.24 Collaboration with ten institutions across eight European countries aims
to spur research into medicine use in older adults, with a focus on evidence-based
polypharmacy interventions.
While the US does not have a national strategy to improve appropriate
medication use, the Centers for Medicare and Medicaid Services requires Part D
plan sponsors to establish quality assurance measures “to reduce medication
errors and adverse drug interactions and improve medication use.”25 At a
minimum, these measures must include both concurrent and retrospective drug
utilization review (DUR) systems. Concurrent DURs must screen for therapeutic
duplication, age and gender-related contraindications, over- and under-utilization,
drug-drug interactions, incorrect dosage and duration of therapy, and drug-allergy
contraindications. Additionally, Part D plan sponsors are required to offer
Medication Therapy Management (MTM) programs to beneficiaries with multiple
chronic diseases and who are using multiple medications in order to “optimize
therapeutic outcomes through improved medication use.”25 Both DUR and MTM
program requirements are codified in regulations found at 42 CFR § 423.153.13.
While neither of these programs are targeted specifically at improving appropriate
prescribing or reducing potentially inappropriate medication use, the population
served by Medicare Part D prescription drug plans could benefit greatly from
targeted programs.
1.2.1 Cognition as a Driver of Medication Management
One particular health outcome of extreme importance in today’s society is cognitive
decline. Alzheimer’s Disease and related-dementias are now the fifth-leading
cause of death globally;26 in the US at least 1 in 9 people over 45 years of age
experience subjective cognitive decline.27 In addition to cognitive decline being an
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extremely prevalent condition, subjects with dementia or cognitive impairment
have as many comorbidities as similar cognitively-intact persons, and take on
average at least five medications daily.28 Despite having a similar burden of
comorbidity, people living with dementia more commonly use certain medication
classes such as antidepressants and antipsychotics28 that have been shown to
worsen cognitive decline. While older adults in general are more susceptible to
ADRs than their younger counterparts due to pharmacokinetic changes,29,30 older
adults with dementia may be even more sensitive to cognitive adverse events than
similar cognitively-intact older adults due to changes in the permeability of the
blood-brain barrier.31,32 For some individual medications or medication classes,
there is ample enough evidence to support their link to cognition that deprescribing
guidelines have been developed. These include proton-pump inhibitors,33,34
benzodiazepines,35 and certain psychotropic medications.36
These

facts

highlight

the

importance

of

appropriate

medication

management in older adults at risk for and living with cognitive impairment. Access
to medication appropriateness tools that have been externally validated and shown
to be associated with cognitive decline is an invaluable tool for healthcare
providers when making important medication therapy optimizations.
1.2.2 Measuring Medication Appropriateness
While medication management is an essential component in the medical care of
older adults (including those with or at risk for cognitive impairment), simply
understanding the importance of medication management is not enough to be able
to implement it consistently and effectively in both clinical practice and research.
Indeed, the first step to implementing assessment of medication appropriateness
into all necessary aspects of clinical care is to accurately and specifically define
exactly what one is measuring when assessing "appropriateness."
In general, to measure appropriate prescribing, one must consider not only
the avoidance of inappropriate medications, but also the appropriate use of
indicated medications, monitoring for adverse events, avoidance of drug-drug
interactions, and ensuring that the care provided optimizes the patient’s choice.37

5

Fortunately, researchers have developed tools that aim to facilitate the
identification of both appropriate and potentially inappropriate medications (PIMs)
in an effort to optimize medication therapy. These tools range from long lists of
explicit criteria that define PIMs to calculated formulas that give scores based on
risks. Some tools require extensive clinical judgement, while others are easily
automated and require little patient-specific information. Each tool addresses
different appropriateness indicators, ranging from patient adherence, ADRs, DDIs,
contraindications, alternative therapies, clinical efficacy, medication regimen
complexity, cost-effectiveness, dosage, duplication, indication, under-prescribing,
specific safety issues, and other inappropriate prescribing. The plethora of tools
available to clinicians to guide prescribing decisions can be overwhelming, so
efforts are being undertaken to validate these tools. Unfortunately, some have
been more extensively researched than others.
Measurements for prescribing appropriateness can be either explicit or
implicit. Explicit measures of prescribing appropriateness generally consist of lists
of criteria that should be considered “inappropriate” and are the most commonly
used, with one study finding that almost 62% of prescribing appropriateness
assessment tools were criteria-based.38 These measures are generally developed
using expert opinions or consensus techniques, as there is a dearth of evidence
on important treatment decisions in geriatrics.39
While explicit measures are easily applied in practice as they require no indepth clinical reasoning, they also do not generally address patient preferences or
the nuances of multi-morbidity. Conversely, implicit measures require practitioners
to use patient-specific information to guide decisions about prescribing. In this
sense, implicit measures tend to be more patient-centric, rather than medicationcentric. Additionally, implicit measures commonly include scoring systems to aid
healthcare providers in decision making. Despite the importance and potential
benefits of using these types of measures, they are time-consuming and difficult
to apply in practice.
Both explicit criteria and implicit guides are utilized by healthcare providers
working with older adults, but it can be difficult to determine which measure best
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meets the provider and patient’s needs. One recent systematic review identified
42 prescribing appropriateness tools, which varied not only in their format (explicit
vs. implicit), but also in their focus on stopping inappropriate and starting
appropriate medications, suggesting alternative treatment strategies, and whether
dosing was considered.38
As noted previously, determining whether a medication or medication
regimen is appropriate is a nuanced process, involving consideration of more than
20 distinct clinical providers.16 Determining how to measure the appropriateness
of medication(s) in research is no less complicated. Each of the more than 40
different medication appropriateness tools has been used in a variety of manners
and combinations to assess medication appropriateness in research studies. A
recent systematic review found that nearly one-third of studies that assessed
medication appropriateness used multiple tools to do so, and almost 90% did not
use the complete clinical tool, but a version of it.40
While much research has been dedicated to developing measures of
prescribing appropriateness, few of these measures have been externally
validated and correlated with patient outcomes. There has certainly been progress
in this arena, evidenced by a systematic review published in 2007 finding only 18
studies that linked various prescribing appropriateness measures to health
outcomes, while another published in 2018 found 53 separate studies.37,38 Still,
only about one-third of available tools have ever been investigated for association
with any patient outcome,38 highlighting the need for more patient-centered
prescribing appropriateness measures.
1.3

Cognitively Targeted Medication Appropriateness Assessment Tools

Though there are many tools available to both researchers and clinicians, only six
of them have ever been investigated with regards to their relationship to cognitive
outcomes. Here, we present a brief description of each of these tools, including
their development and relevant external validation studies. They are presented in
order of their initial publication. A summary of these tools can be found in Table
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1.6.1, while a summary of studies investigating the tools’ association with cognitive
decline is detailed in Table 1.6.2.
1.3.1 Beers Criteria
What is now known as the Beers criteria began as a list of 30 therapeutic classes
and medications that should be avoided in older adults residing in nursing homes.
Compiled by geriatrician Mark Beers and a consensus panel of experts and
published in 1991, the Beers criteria was one of the first sets of explicit criteria to
identify PIM use.28 The Beers criteria were subsequently updated in 1997 and
2003, followed by a major reformation in 2012 to more closely follow evidencebased medicine guidelines. Over time, the Beers criteria have evolved to be
applicable to all older adults, and the 2015 and 2019 versions of Beers criteria now
include five different types of criteria including: potentially inappropriate
medications in most older adults, medications that should be avoided only in
certain health conditions (DZIs), medications that should be used with caution,
drug-drug interactions (DDIs), and recommended dose adjustments based on
kidney function.42,43
The Beers criteria are thus intended for use by clinicians treating adults
aged 65 years or older in all ambulatory, acute, and institutionalized settings, and
its creators urge that the criteria "not be applied in a punitive manner", but rather
as an opportunity for education and quality improvement.43 Being the most
commonly used tool to assess medication appropriateness assessment tool in the
literature,40 the Beers criteria have been extensively studied for their relationship
with a number of health outcomes, but only a few studies have considered
cognitive outcomes. In one large database study with over 70,000 subjects, Beers
“high-severity” (BHS) anticholinergics were not associated with delirium or
hallucinations after one year, but BHS narcotics were. In another database study
investigating drug-related problems (DRPs) as defined by ICD-9 codes, 1.45% of
PIM users experienced “any cognitive impairment” (definition not specified)
compared to 0.51% of non-PIM users (OR [95% CI] 2.88 [2.05-4.04]).44
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Neither study used the 2015 Beers criteria, and no studies have been
published using the updated criteria that were released in January 2019. For the
2019 criteria, two medications no longer on the US market were removed and a
number of medications to be used with caution in older adults with certain
conditions were also removed because they are not uniquely inappropriate to older
adults. Specific for our population of interest, histamine-2 receptor antagonists
were removed from the list of medications to be avoided in older adults with
dementia due to weak evidence and to avoid overly restricting therapeutic options
given the strong evidence against use of proton pump inhibitors33; aripiprazole was
also removed as a preferred agent in Parkinson disease due to both safety and
efficacy concerns.
The 2019 update also added 3 PIMs, 4 medications to be used with caution,
2 DZIs, and 7 DDIs. The added DZIs and DDIs are significant because these
categories of PIMs make Beers criteria the only among the six tools studied for
cognitive outcome associations that has any patient-specific recommendations.
1.3.2 Anticholinergic Drug Scale
The investigators who developed the Anticholinergic Drug Scale (ADS) did so with
the recognition that the relationship between delirium and anticholinergic
medications was wrought with poor measurement of anticholinergic exposure, but
using serum anticholinergic activity was too cumbersome to be done routinely. In
a prospective cohort study published in 2001, they designed the ADS by having
geriatric clinicians independently rate each of 340 medications from 0 (no
anticholinergic activity) to 3 (marked anticholinergic activity) based on their clinical
experience.45 Individual medication scores are summed for a total ADS. . A later
pilot study in 200246 and validation study published in 200647 expanded the ADS
and confirmed that it correlated well with serum anticholinergic activity.
While multiple studies have used the ADS to define PIMs in populations
with cognitive impairment,48,49 few validation studies have been conducted to
determine its ability to predict cognitive decline. One retrospective cohort study did
find a positive association between the ADS and cognitive decline when defined
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using a multiple of measures,50 but another prospective cohort study failed to find
an association between cognitive decline in already-demented patients with an
ADS score of >3.51 Other, non-validation studies have found conflicting results
regarding the relationship between ADS and cognitive decline. The ADS has been
correlated with cognitive decline in subsets of populations with depression and
schizophrenia. One case-control study found that use of medications with ADS
score ≥ 2 was associated with risk for dementia (OR [95% CI] 1.26 [1.22-1.29]) in
an elderly population with depression,52 while another considered patients with
schizophrenia and found that those with ADS scores ≥4 performed more poorly on
a cognitive test than those with ADS < 4.53 However, a retrospective cohort study
found no association between the ADS of bladder antimuscarinics and cognitive
performance in a large sample of older adults in long-term care.54
1.3.3 Sedative Load
The Sedative Load tool was first published in 2003 and divides sedative
medications into four classes: primary sedatives, drugs with sedation as a
prominent side effect, drugs with sedation as a potential adverse effect, and drugs
with no known sedation.55 Investigators searched the compendium of prescription
drugs available in Finland from 1998-2001 using the key words of sedating,
sedative, drowsiness, sleepiness, lassitude, exhaustion, tiresome, and fatigability.
Sedative load – like the ADS – is a scoring tool that includes only regularly
scheduled prescription medications (not those used as-needed). Primary
sedatives receive a Sedative Rating of 2, while drugs with sedation as a prominent
side effect receive a rating of 1. The individual ratings of each medication are
summed for the total Sedative Load.
No studies have successfully linked PIM use as measured using the
Sedative Load with cognitive decline. In a cross-sectional study of communitydwelling older men in Australia, there was no relationship between participants
with any level of Sedative Load and cognitive impairment.56 Interestingly, one
prospective cohort study comprising 1,444 long-term care residents in Finland
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actually found a statistically significant relationship between having a higher
sedative load and not being diagnosed with dementia (p=0.009).57
1.3.4 Drug Burden Index
The Drug Burden Index (DBI) was first reported in 2007, and is one of the few
prescribing appropriateness tools that explicitly considers over-the-counter (OTC)
medications in addition to prescription medications.58 One of the things that makes
the DBI unique is that it is primarily based on dosing. The DBI has been studied in
Australia, Canada, Finland, New Zealand, the Netherlands, the United Kingdom,
and the US.59
To develop the DBI, investigators first designed a formula to quantify “total
drug burden,” (TDB) based on physical and mental health outcomes using data
from the Physicians’ Desk Reference60 and Mosby’s Drug Consult61. TDB
considers 1) drugs with anticholinergic effects (AC), and 2) drugs with sedative
effects (S). Investigators hypothesized that the burden of AC and S medications
would be linearly associated with physical and cognitive function, both via the
presence of these medications and the extent of their exposure. Accordingly, the
DBI is based predominantly on dosing of AC and S medications. Each medication
receives an individual DBI score between 0 and 1, and the total DBI is calculated
as in Equation 1.1, where the pharmacological effect (E) of AC and S drugs is
calculated based on the daily dose (D) and the minimum daily dose according to
the Food and Drug Administration (ẟ) where ⍺ represents a constant. A total DBI
of ≥1 is considered “high.”

Equation 1.1. Pharmacological Effect
𝐸𝐸
𝐷𝐷
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐷𝐷𝐷𝐷𝐷𝐷 = = �
𝛼𝛼
𝛿𝛿 + 𝐷𝐷

The DBI has been extensively externally validated and positively associated
with five patient-specific health outcomes (hospitalization, mortality, falls, cognitive
decline, and functional decline). The initial published report found a significant
positive association between DBI and cognitive function as measured using the
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Digital Symbol Substitution Test in a cross-sectional study.58 However, this is only
one of four validation studies specifically exploring the relationship between
cognitive outcomes and DBI. While one medical chart review found that a high DBI
(≥1) was associated with nearly three times the odds of a hospital admission for
delirium (OR [95% CI] 2.95 [1.34-6.51]),62 another found no association between
DBI and cognitive function as measured by the Abbreviated Mental Test.63 A
subsequent retrospective cohort study consisting of community-dwelling older men
found no relationship between DBI exposure and cognitive impairment measured
with two different performance tests.64 Still another retrospective cohort study
found consistent positive associations between the anticholinergic component of
the DBI and cognitive decline defined with a multitude of measures.50
1.3.5 Anticholinergic Cognitive Burden Scale
Like the DBI and ADS, the Anticholinergic Cognitive Burden Scale (ACBS) is also
a scoring tool with a focus on anticholinergic medications.65 For this tool,
anticholinergic activity of medications was determined based on a literature review
of serum anticholinergic activity.66 A medication was scored as 0 if there were no
laboratory tests or clinically relevant cognitive effects, 1 if there were only
laboratory tests, and 2 or 3 if there were both. ACBS scores of 1 indicate “possible”
anticholinergic effects, whereas scores from 2-3 indicate “definite” anticholinergic
effects.
The ACBS is the prescribing appropriateness tool that has been most
extensively studied for its relationship with cognitive outcomes. Many of the studies
have included long follow-up and large sample sizes. Additionally, the studies have
considered nuanced definitions of exposure, including continuous vs intermittent
use and measurement of the ACBS as a continuous vs categorical exposure
variable. A retrospective cohort study with a follow-up time of one year found an
increased risk of cognitive decline whether AC exposure was measured by
duration, number dispensed at the same time, or using the ACBS.67 Another
longitudinal observational study of 1,652 community-dwelling African Americans
over the age of 70, investigators found that while the risk for mild cognitive
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impairment or dementia after 6 years increased with the number of definite
anticholinergic medications (OR [95% CI] 1.46 [1.07-1.99]), there was no
association between the number of possible anticholinergic medications and risk
for cognitive decline (OR [95% CI] 0.96 [0.85-1.09]).68 Another longitudinal study
found similar results after 2 years when measuring cognitive decline using mini
mental state examination.69
1.3.6 Anticholinergic Risk Scale
The Anticholinergic Risk Scale (ARS) was developed in response to the lack of
specificity of Beers criteria in its association with cognitive outcomes. Medications
with known potential to cause anticholinergic adverse effects were identified by
three experts (one physician and two pharmacists) who ranked each based on
their potential to cause anticholinergic adverse effects on a scale from 0 (no risk)
to 3 (high anticholinergic potential). The total ARS score is the summation of
individual ARS scores for each medication.
In the initial published report detailing ARS, investigators focused on the
adverse effects of anticholinergic medications, dividing them into central effects
(i.e., falls, dizziness, or confusion) and peripheral effects (i.e. dry eyes, dry mouth,
and constipation). This investigation found that in both a retrospective and
prospective cohort study of older adult inpatients, higher ARS scores were
associated with a higher risk for central ADRs.70 Another prospective cohort study
found that higher ARS scores were also associated with poorer performance on a
number of neuropsychological cognitive performance tests,50 and a crosssectional study also found an association between cognitive performance and
ARS.71 However, one chart review did find no relationship.63
Among these six tools (Beers criteria, ADS, Sedative Load, DBI, ACBS, and ARS),
the strongest support from the literature for a relationship between the
measurement tool and cognitive outcomes is for the ACBS. In addition to it being
the most extensively studied with regards to cognitive outcomes, there were also
no published studies with negative results. However, it should be noted that while
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the other tools have been used in papers written by investigators other than those
who developed it, the ACBS has only been utilized in papers authored by the
original investigators.
The ADS, DBI, ACBS, and ARS tools all have scoring systems and focus
heavily (or exclusively) on anticholinergic medications. Conversely, the Beers
criteria is a much more extensive list of medications that is compiled into a list of
explicit criteria, while the Sedative Load tools focuses only on medications with
sedative effects. Some have argued that explicit criteria are more easily applied in
practice,72 and others have suggested that the sheer volume of medications
included in explicit criteria make them too cumbersome for practice. Tools with a
scoring system may be more easily implemented by healthcare providers as they
could be integrated with computer systems and output a single score for clinical
assessment.

1.4

Other Medication Appropriateness Assessment Tools

As noted previously, while only six medication appropriateness tools have been
investigated for their relationship with cognitive outcomes, there are more than 40
tools available to both researchers and clinicians. In a recent systematic review,38
investigators identified nine tools that used scoring systems to quantify PIMs; five
of these have been noted above to have been investigated in relationship to
cognitive outcomes (ACBS, ADS, ARS, DBI, and Sedative Load). The other 33
tools identified did not have scoring systems, and included the Beers criteria
discussed above.
All but one of the tools with a scoring system has been externally validated
for any health outcome, while only five of the tools without scoring systems have
been externally validated. Of these, most have only been investigated in one or
two external validation studies.73–75 Conversely, the Beers criteria has been
positively associated not only with cognitive outcomes, but also with
hospitalizations, falls, mortality, functional decline, and ADRs in 4 out of 8 other
studies.76–79 The only other medication appropriateness assessment tool that has
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been as extensively studied as the Beers criteria is the Screening Tool of Older
Person's Prescriptions (STOPP). Created in 2008 by expert consensus in the
European Union80 and updated in 201581, STOPP is similar to Beers in that it
consists of an extensive list of medications that may be potentially inappropriate
for older adults. When used to measure PIM use, it too has been positively
associated with hospitalizations, mortality, falls, functional decline, ADRs, and
quality of life in six different investigations.82–87
There is significant cross-over between the medications present in the Beers
and STOPP tools, with the major difference being that Beers criteria is
predominantly used in North America, while STOPP is mainly utilized in Western
Europe. Furthermore, STOPP has been directly compared to Beers criteria in its
ability to identify PIM use in older adults. In fact, STOPP has been found to identify
more PIMs than Beers criteria in older adults in numerous investigations.88–95
Thus, while only the ADS, ACBS, ARS, Beers criteria, DBI, and Sedative
Load have been formally associated with any cognitive outcome in the published
literature, it is reasonable to consider STOPP as another medication
appropriateness assessment tool that may be useful in defining PIM use as it
relates to cognitive outcomes given its similarity and potential superiority to the
Beers criteria.

1.5

Specific Aims

While targeting cognition when managing medications in older adults may be a
relatively new product of a rapidly shifting healthcare landscape, the need for
improving measurement of medication appropriateness is extensive nonetheless.
Without widespread consensus as to what measure of PIM use is the best to use
when studying the propensity of medications to cause cognitive decline, clinicians
will not have the information they need to improve outcomes for their patients. As
the world awaits further developments that may one day produce an effective
treatment (or even cure) for the terrible brain-destroying disease of dementia, we
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can take steps today to improve medication therapy and potentially dampen the
horrific impact of dementia on the lives of older adults and their loved ones.
In this work, we set out to examine the issue of measuring medication
appropriateness to target cognitive outcomes with the intent of informing future
research and clinical practice. While the gold-standard in evidence generation
remains synthesis of data from randomized placebo-controlled clinical trials, we
have seen that systematic reviews are unable to coalesce data from even the most
rigorously performed trials if there is no consistency in the definition of
"inappropriate medication." Groundwork must be laid to provide crucial validation
and consensus to the measurement of medication appropriateness in light of
cognition, and then it must be applied to numerous prospective research
endeavors in order to provide a synthesized evidence-base for how medications
should be managed to ensure appropriate use in older adults wishing to preserve
cognition or prevent cognitive decline.
In this first section, we have provided a historical context for the importance
of medication management, described worldwide approaches to medication
management in older adults, and provided an overview of the available tools that
have been used to measure medication appropriateness with a perspective toward
cognition.
Section two will utilize a number of these tools to estimate prevalence of
potentially inappropriate medication use in various populations of American older
adults.
The next section will use different methodological techniques and data
sources to explore how some of these tools may or may not be associated with
cognitive decline in older adults. We will define both PIM use and cognitive decline
in a variety of ways to determine the effect varying definitions may have on
associations and effect sizes.
Finally, we will explore how the findings provided in this work may be applied
to clinical practice, future research endeavors, and governmental policies.
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1.6

Tables and Figures

Table 1.6.1. Prescribing Appropriateness Tools for Cognitive Outcomes
Year
Scoring
Drug class focus
Dosing
Created
System
Beers 1991
None
Mentions
ADS 2002
Anticholinergics
Based predominantly
✓
Sedative Load 2003
Sedatives
Does not consider
✓
DBI 2007
Anticholinergics & sedatives
Based predominantly
✓
ACBS 2008
Anticholinergics
Does not consider
✓
ARS 2008
Anticholinergics
Does not consider
✓
ACBS: Anticholinergic Cognitive Burden Scale; ARS: Anticholinergic Risk Scale; DBI: Drug Burden Index
Tool

Explicit
Criteria
✓

17

Table 1.6.2. List of Studies Investigating Cognitive Outcomes and PIMs
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Exposure
ACBS, ADS,
ARS, DBI
ACBS
ACBS
ACBS
ACBS, ARS
ADS
ADS
ADS
ARS
ARS, DBI

Author

Year

Kashyap50

2014

Campbell68
Fox69
Cai67
Pasina71
Kersten51
Chatterjee52
Eum53
Rudolph70
Bostock63

2010
2011
2013
2013
2013
2016
2017
2008
2013

Outcome
Cognitive battery

Design
P. cohort

N

Setting

102 Community

Finding
+

MCI/Dementia
P. cohort
1,652 Community
+/MMSE
P. cohort
12,423 Community
+
Dementia
R. cohort
3,690 Community
+
SBT
Cross-sectional
1,380 Inpatient
+
CERAD, MMSE
P. cohort
87 LTCF
Dementia
Case-control
28,388 LTCF
+
BACS
P. cohort
483 Community
+
Confusion
P. cohort
132 Inpatient
+
AMT
Chart review
271 Inpatient
Cognitive
Beers 2003
Fick44
2008
R. cohort
17,971 Community
+
impairment
Beers 2012
Stockl78
2010 Delirium
R. cohort
74,716 Community
+/58
DBI
Hilmer
2007 DSST
Cross-sectional
3,075 Community
+
DBI
Gnjidic64
2012 ACE, TMT
R. cohort
887 Community
62
DBI
Best
2013 Delirium admit
Chart review
329 Inpatient
+
57
Sedative load
Taipale
2009 Dementia
P. cohort
1,444 LTCF
Sedative load
Gnjidic56
2012 MMSE
Cross-sectional
1,696 Community
ACBS: anticholinergic cognitive burden scale; ACE: Addenbrooke’s cognitive examination; AMT: abbreviated mental test;
ARS: anticholinergic risk scale; BACS: brief assessment of cognition in schizophrenia; CERAD: Consortium to Establish
a Registry for Alzheimer Disease neuropsychological test battery; DBI: drug burden index; DSST: digital symbol
substitution test; LTCF: long-term care facility; MDS CPS: minimum data set cognitive performance scale; MMSE: mini
mental state examination; P. cohort: prospective cohort; R. cohort: retrospective cohort; SBT: short blessed test; TMT:
trail making task
+: Significantly associated with outcome measure; -: Not significantly associated with outcome measure

Figure 1.6.1. Prescribing Cascade
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Figure 1.6.2. Good Prescribing Recommendations
Good Prescribing Recommendations
1.
2.
3.
4.
5.
6.
7.
8.

Evaluate and clearly define the patient's problem;
Specify the therapeutic objective;
Select the appropriate drug therapy;
Initiate therapy with appropriate details and consider nonpharmacologic therapies;
Give information, instructions, and warnings;
Evaluate therapy regularly (e.g., monitor treatment results, consider discontinuation of the drug);
Consider drug cost when prescribing;
Use computers and other tools to reduce prescribing errors

Figure 1.6.3. Balancing Prescribing Decisions
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2

EXTENT OF POTENTIALLY INAPPROPRIATE MEDICATION USE
2.1

Introduction

In 2016, 15.2% of the US population was aged 65 years and over, representing
49.2 million Americans: a 33% increase from only ten years prior.96 85% of these
older adults reported using at least one prescription medication, which has
remained relatively constant since 2007.97 However, there has been a marked
increase in the number of older adults using five or more prescription medications
from 27.1% at the start of the 21st century, to 39.1% between 2009-2012, and
finally to 40.9% between 2013-2016.98 While the increased number of medications
used by older adults may be clinically appropriate due to increased multimorbidity,
it is important to note that many of the most commonly used medications in this
population may be potentially inappropriate. For example, 24.1% of adults aged
65 years and over used prescription proton pump inhibitors or histamine-2 receptor
antagonists from 2011-2014, 16.4% used prescription analgesics, and 18.9% used
antidepressants.99 Medications in each of these classes are included in numerous
medication appropriateness assessment tools as potentially inappropriate for all
older adults, regardless of indication.
Thus we can see that potentially inappropriate medication (PIM) use is a
widespread phenomenon in the US. However, the aforementioned trends are not
unique to the Americas, nor to a specific definition of PIM use. Numerous studies
throughout the world have provided estimates of PIM use in community-dwelling
older adults in the last decade ranging from 15.3%100 – 72.9%93 when PIM use is
defined as concurrent use of ≥5 medications, and 22.7-77.3%95 when medications
in the 2003 Beers Criteria or STOPP version 1 are considered PIM use. Even when
more specific definitions of PIM use are used to estimate prevalence (such as
anticholinergic-specific

medication

appropriateness

assessment

tools),

prevalence remains high (9.56%101 -43%48), especially for those with dementia.
PIM use in older adults is not a monolithic term, nor can it be used to reliably
describe any one characteristic of medication use. In this section, we use two
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different data sources and various medication appropriateness assessment tools
to define PIM use in order to add to the literature of PIM use prevalence estimates.
In the first study, we utilize medication self-reported data from initial visits to an
Alzheimer's Disease Center between 2005-2018 to estimate the prevalence of PIM
use in general. To do so, we defined PIM use as ≥1, ≥4, and ≥5 medications in the
Beers criteria and STOPP, as well as use of ≥4 and ≥5 medications total
(polypharmacy). The next study narrows the definition of PIM use to include only
medications suspected to be associated with negative cognitive outcomes, using
the sublist of medications considered potentially inappropriate for individuals with
dementia from the Beers criteria, as well as use of medications considered to be
anticholinergic according to the Anticholinergic Drug Scale. This study utilizes
administrative prescription claim data from a population of older adults with feefor-service Medicare and Medicare Part D and provides prevalence estimates from
2012-2016. Both studies stratify estimates by the presence of baseline cognitive
impairment or clinical dementia in order to demonstrate whether PIM use
prevalence is different in these two populations.

22

2.2

Prevalence of Potentially Inappropriate Medication Use in Older
Adults: A Comparison of Measurement Tools

2.2.1 Background
Over the past century, the US population has been steadily aging. By 2050, it is
estimated that almost one-quarter of the US will be 65 years of age or older,
second only to Europe in age.102 Aged individuals bear a high burden of
comorbidity, and those aged 65 or older are especially afflicted, with 15% of
community-dwelling individuals having four or more chronic health conditions,
compared to only 6.7% of a similar population of individuals 55-64 years old.6
Because of this, more than nine out of ten individuals aged 65 years and older use
at least one prescription medication, while over 40% use five or more (i.e.
polypharmacy).98 With higher rates of comorbidities and polypharmacy in addition
to changes in pharmacokinetic and pharmacodynamics profiles, the geriatric
population is at risk for a higher rate of ADRs, including both drug-disease and
drug-drug interactions.103
One subset of individuals within this population that is at an especially high
risk for ADRs are those with cognitive impairment (CI). Individuals with CI may take
medications that are potentially inappropriate for their age and condition. In fact,
some studies have estimated that as many as half of adults with dementia take
potentially inappropriate medications PIMs with a high potential for ADRs.104,105
PIM use in older adults has been associated with hospitalization and
mortality, as well as cognitive decline, falls, and functional impairment.38 Thus, it is
important for healthcare providers serving older adults to appropriately prescribe
and manage medication therapy to optimize health outcomes. Unfortunately, there
is no universally-accepted method for identifying PIM use in older adults generally,
nor in the CI population. In addition, no method has consistently been shown to be
associated with CI. Over the last 20 years, more than 40 different tools have been
developed to assess PIM in older adults and their use among healthcare providers
varies widely. In this report, we focus on three very commonly-used methods for
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assessing PIM use: presence of polypharmacy and use of medications present in
the Beers or STOPP criteria.
Unfortunately, each of these tools often result in drastically different
estimations of the prevalence of PIM use. It is clear from the literature that the
prevalence of PIM use varies widely amongst populations, both within a single set
of criteria and between different criteria. For instance, in the long-term care
population PIM prevalence ranged from 21-63% with Beers 2003 criteria, 63-83%
with Beers 2012 criteria, and 24-80% with STOPP criteria.105 In a cross-sectional
study of community-dwelling elderly adults, PIM prevalence was assessed as
18.7%, 37.3%, and 40.4% using STOPP version 1, Beers 2012, and STOPP
version 2 criteria respectively.93
In this study, we aim to estimate the prevalence of PIM use for those with
and without cognitive or functional impairment.

2.2.2 Methods
2.2.2.1 Study Design and Population
In this study, we utilize data obtained from participants at Alzheimer’s Disease
Centers (ADCs) throughout the United States. The US National Institute on Aging
(NIA) began the ADC program in 1984 in a comprehensive effort to boost research
on both Alzheimer disease and related disorders.106 Today, there are 39 Centers
at major medical institutions throughout the United States receiving funding from
the NIA. As part of their participation in the ADC program, Centers prospectively
collect demographic, clinical, neuropsychological, and diagnostic patient data and
provide it to the National Alzheimer’s Coordinating Center (NACC) in a
standardized manner. NACC then deidentifies the data and makes it available to
researchers in the form of a Uniform Data Set (UDS).107
This analysis used data from all reporting ADCs for UDS visits conducted
between June 2005 and August 2018. We utilize a cross-sectional study design to
assess the prevalence of PIM use for those with and without cognitive impairment.
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Subjects were included if they were at least 65 years of age, reported living
in the community (in a private residence, independent living facility, or senior
community), and reporting at least one medication at the initial ADC visit.
2.2.2.2 Measurement
We considered eight different PIM definitions based on polypharmacy (≥4 and ≥5
total medications) and the number of medications present in existing explicit
criteria (≥1, ≥4, and ≥5 PIMs as mentioned in the 2015 update of the Beers
criteria42 and version 2 of STOPP81). Each of these medication appropriateness
assessment tools is widely used both in research and clinical practice. While use
of medications in the Beers criteria has been investigated in relationship to
cognition,44,78 the STOPP criteria have been shown to be more sensitive at
detecting PIM use than the Beers criteria.91,93 Polypharmacy was included as a
measure of PIM use in addition to the explicit criteria as it is commonly considered
inappropriate to use ≥5 medications.15
In addition to evaluating PIM use with different definitions of the three tools
noted above, we this investigation also included information on cognitive
impairment baseline. CI was measured as the presence of at least mild cognitive
impairment using the CDR global score (CDR-GLOB) ≥ 0.5. CDR-GLOB is a
reliable and well-validated method of measuring cognitive and functional status in
many studies in the field.108
Information on demographic characteristics at baseline including sex, age,
years of education, marital status, and race was also collected. In addition,
subjects’ clinical profiles were documented by recording the presence
(recent/active or remote/history) of the following conditions: atrial fibrillation,
congestive heart failure, depression (within the last two years), diabetes, heart
attack, hypercholesterolemia, hypertension, Parkinson’s disease, seizures, stroke,
transient ischemic attack, and urinary incontinence.
2.2.2.3 Statistical Analysis
Normality for all variables was assessed visually with Q-Q plots, and normally
distributed continuous variables were described using the mean and standard
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deviation (SD), while the median and interquartile range (IQR) were used to
describe non-normally distributed variables. Chi-squared, Student’s t, and
Wilcoxon Mann-Whitney U tests were used to compare subject characteristics as
appropriate.
All statistical analyses were conducted in SAS 9.4.109

2.2.3 Results
2.2.3.1 Study Population
The participant selection process is detailed in Figure 2.2.1. After applying all
inclusion and exclusion criteria, the sample size was 26,311 participants.
As can be seen in Table 2.2.1, the mean (SD) age of participants included
was 75.7 (6.9) years, and over half (56.3%) were female. The majority of
participants were well-educated (median 16 years of education), white (81.2%),
and were married or living as married (63.9%). Additionally, 73% of participants
went to the ADC primarily to participate in a research study. While nearly half
(45.7%) of participants had ever smoked cigarettes, only 3.7% had done so in the
last 30 days. The most prevalent comorbidities in this sample were hypertension
and hypercholesterolemia, followed by depression and urinary incontinence (53.8,
51.7, 28.6, and 16.7% respectively).
2.2.3.2 Baseline CI and PIM Use Prevalence
Of included participants, 23.7% had CI at baseline. Regardless of baseline CI, the
highest prevalence of PIM use was identified when defined as ≥4 total medications,
followed by ≥5 total medications, ≥1 medication in STOPP criteria, then ≥1
medication in Beers criteria (74.6, 63.2, 43.9, and 30.5% respectively). There were
statistically significant differences (p<0.0001) in the proportion of participants with
CI based on all PIM use measurements except ≥1 medication in STOPP criteria
(p=0.15).
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2.2.4 Discussion
In this study, we show that in a population of adults aged 65 years or over seeking
care at ADCs, baseline PIM use varied between those with and without CI.
Identification of PIM use with polypharmacy found the greatest number of PIM
users, followed by report of any medication in STOPP and Beers criteria.
Other studies have explored the performance of these measures to identify
PIM use, and findings in this study are consistent with what is available in the
literature.110 It is important to note that most medications included in both the Beers
and STOPP criteria are not known to have adverse effects on cognition. In Beers
criteria, less than half of the 38 rationales given for classifying medications as
potentially inappropriate for all adults aged 65 years and older indicate that the
medication (or class) may be associated with adverse cognitive or functional
outcomes. However, inappropriate prescribing may be an indicator of other poorlymanaged health conditions which may be associated with CI.
Furthermore, there may be more appropriate PIM measurement methods
to consider when analyzing PIM use and CI. While using cut-off values is common
in the literature and in clinical practice, there is debate as to the extent to which
dichotomizing appropriate prescribing is an effective way to optimize health
outcomes. The eight definitions using three PIM measurement tools investigated
herein may not be the most optimal choice. In one randomized controlled study,
investigators assessed appropriate medication therapy using the START/STOPP
criteria as a gold standard, and determined the ability of different polypharmacy
cut-offs to differentiate between appropriate and inappropriate medication
regimens.111 Their findings suggested that no polypharmacy cut-off was
differentiated acceptably well, as the sensitivity-specificity trade-off was too steep.
These investigators recommended that appropriate prescribing is context-specific
and thus that general cut-offs would always be sub-optimal. Future studies should
approach PIM use measurement in a more nuanced and clinically relevant
manner.
Overall, this study supports the current literature that PIM use is highly
prevalent in community-dwelling older adults both with and without CI. There are
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many opportunities to enhance this area of research in the hopes of providing
patients and their healthcare providers with more effective tools to manage
medication therapy in order to optimize cognitive and functional outcomes.
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2.2.5 Tables and Figures
Table 2.2.1. Baseline Characteristics
Demographics
Female, n (%)
Age, mean (SD)
Years of education, median (IQR)
Race
White
Black or African American
Asian
Other
Unknown
Marital Status
Married or living as married
Widowed
Divorced or separated
Never married
Other or unknown
Primary Reason for Coming to ADC
To participate in research study
To have a clinical evaluation
Both of above
Unknown
Visits to an ADC, median (IQR)
Health Behaviors, n (%)
Ever smoker
Smoked in last 30 days
Drank alcohol in last 3 months
Health Conditions, n (%)
Atrial fibrillation
Cognitive impairment
None
Questionable
Mild
Moderate
Severe
Cognitive impairment family history
Congestive heart failure
Depression in last 2 years
Diabetes
Heart attack
Hypercholesterolemia
Hypertension
Parkinson’s disease
Seizures
Stroke
Transient ischemic attack
Traumatic brain injury
Urinary incontinence

Total
n = 26311

Impaired
n = 6240

Unimpaired
n = 20071

14799 (56.25)
75.70 (6.94)
16 (12-18)

3315 (53.13)
77.32 (7.01)
14 (12-16)

11484 (57.22)
75.19 (6.84)
16 (13-18)

21353 (81.16)
3595 (13.66)
580 (2.20)
664 (2.52)
119 (0.45)

4986 (79.9)
826 (13.24)
108 (1.73)
285 (4.57)
35 (0.56)

16367 (81.55)
2769 (13.8)
472 (2.35)
379 (1.89)
84 (0.42)

16815 (63.91)
5350 (20.33)
2952 (11.22)
1025 (3.90)
169 (0.64)

4204 (67.37)
1428 (22.88)
436 (6.99)
136 (2.18)
36 (0.58)

12611 (62.83)
3922 (19.54)
2516 (12.54)
889 (4.43)
133 (0.66)

19248 (73.16)
6208 (23.59)
833 (3.17)
22 (0.08)
3 (1-5)

3537 (56.68)
2486 (39.84)
213 (3.41)
4 (0.06)
2 (1-3)

15711 (78.28)
3722 (18.54)
620 (3.09)
18 (0.09)
3 (1-5)

12028 (45.71)
963 (3.66)
2782 (10.57)

2630 (42.15)
244 (3.91)
308 (4.94)

9398 (46.82)
719 (3.58)
2474 (12.33)

2103 (7.99)

471 (7.55)

1632 (8.13)

9952 (37.82)
10119 (38.46)
4251 (16.16)
1455 (5.53)
534 (2.03)
13476 (51.22)
705 (2.68)
7529 (28.62)
3789 (14.40)
1716 (6.52)
14440 (54.88)
14942 (56.79)
624 (2.37)
584 (2.22)
1388 (5.28)
1483 (5.64)
2881 (10.95)
4640 (17.64)

0 (0)
0 (0)
4251 (68.13)
1455 (23.32)
534 (8.56)
3155 (50.56)
210 (3.37)
2574 (41.25)
975 (15.63)
477 (7.64)
3270 (52.4)
3593 (57.58)
191 (3.06)
184 (2.95)
498 (7.98)
420 (6.73)
600 (9.62)
1732 (27.76)

9952 (49.58)
10119 (50.42)
0 (0)
0 (0)
0 (0)
10321 (51.42)
495 (2.47)
4955 (24.69)
2814 (14.02)
1239 (6.17)
11170 (55.65)
11349 (56.54)
433 (2.16)
400 (1.99)
890 (4.43)
1063 (5.3)
2281 (11.36)
2908 (14.49)
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Figure 2.2.1. Participant Selection
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Figure 2.2.2. Potentially Inappropriate Medication Use Prevalence
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2.3

Trends in Potentially Inappropriate Medication Use Among Medicare
Part D Beneficiaries 2012-2016

2.3.1 Introduction
Medication use in older adults can be measured in many different ways.
Information can be gathered from health records at physicians' offices and
hospitals, from pharmacy dispensing records, and directly from patient self-report.
Prescription medication use can also be ascertained from administrative claims
made available through insurance providers and payers, provided that the
medications are processed through an insurance benefit. In the US however, many
older adults did not have access to prescription medication coverage until 2006
when the Medicare Prescription Drug, Improvement, and Modernization Act
created Medicare Part D and in so doing, provided access to a voluntary
medication benefit for Medicare beneficiaries.112 This new program not only
provided critical access to life-saving therapies for a population in dire need, but
also paved the way for researchers to begin to analyze prescription medication
use trends in a large portion of the American population.
Specifically, increased medication use among older adults has given rise to
renewed concerns about potentially inappropriate medication (PIM) use. While a
broad definition of what is considered to be "appropriate" might include patient
wants, scientific rationalism, and the general good,37 clinicians must exercise a fair
amount of clinical judgment when determining whether a medication therapy is
appropriate in the context of certain health outcomes.
For example, the American Geriatrics Society has maintained an explicit list
of medications since 1991 that they consider to be potentially inappropriate in all
older adults, regardless of concomitant medication use or comorbidity. By 2003,
they had added a list of medications that would be potentially inappropriate when
used in the context of 20 diseases/conditions, including dementia.113 The sub-list
of medications considered to be inappropriate for older individuals with dementia
in what is now known as the Beers criteria (Cog-Beers) was compiled based on
medications that the American Geriatrics society considered to have strong
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antipsychotics, and anticholinergics. Because anticholinergics specifically have
been shown to negatively impact cognition in many different studies,67 numerous
tools have been developed to measure their use in this vulnerable population,
including the Anticholinergic Drug Scale (ADS).
In this study, we use Medicare Part D administrative prescription claims
data to estimate the prevalence of PIM use as defined according to the 2012 Beers
Criteria, Cog-Beers, and the ADS in a population of adults 65 years old and above
with and without Alzheimer's disease or related dementias (ADRD) from 20122016.

2.3.2 Methods
2.3.2.1 Population and Study Design
The population for this study was drawn from Medicare Part D (MPD)
administrative claims data provided by the Centers for Medicare and Medicaid
Services (CMS). While MPD is a voluntary outpatient prescription drug benefit for
Americans enrolled in Medicare, approximately 62% of all Medicare enrollees
chose to utilize MPD in 2012, increasing to 72% in 2016.114 Beneficiaries can
choose either a stand-alone plan (which provides administrative claims data
directly to CMS), or can choose to receive all Medicare benefits including
medications through a Medicare Advantage plan (for which CMS does not receive
administrative prescription claims data).
After permission was granted by CMS and the University of Kentucky
Institutional Review Board, we received data for the years 2012-2016 on a random
5% sample of Medicare beneficiaries who had MPD and were ≥65 years old at
some point during 2012-2016, and who had at least some period of being nondually eligible for Medicaid and/or Medicare Advantage was received from CMS.
For the purposes of this study, we included beneficiaries each year from
2012-2016 who were 1) enrolled in a stand-alone PTD plan for the entire year, 2)
33

not dually-eligible for Medicaid at any point during the year, 3) not enrolled in a
Medicare Advantage plan at any point during the year, and 4) at least 65 years old
at the beginning of the year. We were not able to analyze prescription medication
use for beneficiaries enrolled in Medicare Advantage or Medicaid because not all
prescription claims are sent to CMS.
2.3.2.2 Measurements
For each year from 2012-2016, we compared the prevalence of PIM use among
continuously enrolled MPD beneficiaries by applying three PIM criteria. First, we
used the Beers 2012 Criteria115 to identify all beneficiaries who filled any
prescription considered potentially inappropriate for all adults ≥ 65 years old. To
provide prevalence of PIMs that have more evidence of a relationship to cognitive
outcomes, we also defined PIM users each year as those who had any prescription
claims for medications included in the sub-list of Beers 2012 Criteria specifically
for individuals with dementia (Cog-Beers PIMs). Finally, because there have been
numerous studies attempting to validate the ADS47 for its association to cognitive
outcomes, we also identified beneficiaries each who had any claims for
medications classified as anticholinergic according to this scale.
All estimates were stratified by diagnosis of ADRD. Presence of ADRD each
year was determined based on a validated algorithm from the CMS Chronic
Conditions Data Warehouse (CCW).116 If the first date a beneficiary met the criteria
for an ADRD diagnosis was in or before the reference year, the beneficiary was
considered to have ADRD during that entire year. In addition to ADRD, we also
had access to information on the following common chronic conditions: acute
myocardial infarction, anxiety, atrial fibrillation, bipolar disorder, depression,
diabetes, hyperlipidemia, hypertension, and stroke.
2.3.2.3 Statistical Analysis
We used descriptive statistics to summarize baseline characteristics of
beneficiaries continuously enrolled in 2012, including basic demographics and the
common chronic conditions listed above. All information on comorbidities was
identified according to algorithms from the CCW. We present annual period
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prevalence of PIM use according to three criteria for MPD beneficiaries with and
without ADRD from 2012-2016. Additionally, to determine what beneficiary
characteristics are associated with PIM use for each definition, we performed
logistic regressions to estimate odds ratios (OR) and 95% confidence intervals
(CI), adjusting for repeated measures for subjects present in multiple years
assuming an unstructured covariance matrix (see Code Block 2.3.1). In addition to
calendar year, demographic characteristics (age, sex, and race), beneficiary
region (Northeast, South, Midwest, and West), original entitlement reason, and
ADRD in addition to three common psychiatric comorbidities (anxiety, depression,
and bipolar disorder) were also included in this regression. All statistical analyses
were conducted in SAS 9.3.109

2.3.3 Results
After excluding all beneficiaries in each year who were dually eligible for Medicaid
or enrolled in a Medicare Advantage plan, and those who were not at least 65
years old at the beginning of the year, the sample size ranged from 1,337,741 to
1,467,344 between 2012-2016 (34.4% to 46.7% of available beneficiaries) this
analysis (see Table 2.3.1). In 2012, beneficiaries were on average 75 years old,
approximately 60% were female, and over half had hyperlipidemia and/or
hypertension (see Table 2.3.2). 8.1% of beneficiaries were diagnosed with ADRD
in or before 2012, and these beneficiaries were on average 8 years older than
those without ADRD. Those with ADRD had a greater burden of comorbidity
compared to those withut ADRD. Beneficiary characteristics were consistent
across each year of the study, and thus characteristics for 2013-2016 are not
presented, but are available upon request.
A greater proportion of beneficiaries with ADRD were PIM users according
to each definition compared to those without ADRD (see Figure 2.3.1). PIM use
prevalence was highest when defined as a claim for any medication identified in
the Beers 2012 criteria, followed by medications in Cog-Beers, and finally those in
the ADS. In 2012, 51.9% of beneficiaries with ADRD were identified as PIM users
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with the Beers criteria, compared to 43.5 and 38.1% when Cog-Beers and ADRD
were used. For beneficiaries without ADRD, 40.7, 25.8, and 22.3% were identified
as PIM users using the respective definitions. PIM use prevalence was highest in
2013, after which it consistently decreased until 2016. However, PIM use
prevalence remained higher in 2016 than it began in 2012.
Beneficiaries originally entitled to Medicare services due to both disability
and end-stage renal disease had the highest odds of PIM use, regardless of PIM
definition (see Table 2.3.3). The presence of anxiety, bipolar disorder and
depression comorbidities were also highly associated with PIM use of all
definitions. ADRD was associated with between 1.26 – 1.47 times the odds of PIM
use, being most highly associated with ADS PIM use.

2.3.4 Discussion
In this analysis of fee-for-service Medicare beneficiaries enrolled in Medicare Part
D, we have shown that prevalence of PIM use varies over a five-year period
depending on what criteria are used to define it, ranging from about 22% in
beneficiaries without ADRD when measured using the ADS to almost 58% in
beneficiaries with ADRD when measured using the Beers Criteria.
These findings are consistent with other prevalence estimates throughout
the world. A recent systematic review found that when defined as use of
medications in Beers criteria, PIM prevalence ranged from 20.6-80.5% in studies
where cognitive status was reported.117 Although this review only considered
studies of in-hospital patients, the range is similar to what was found in this study.
This study was able to analyze PIM use trends among more than 500,000
older adults living in the United States, making these results widely generalizable
to the approximately 45 million Americans with Medicare Part D benefits.118
However, there are a number of limitations to using this data source to measure
PIM use. While the data used in this study is a rich source of information on
prescription drug use in the older adult population, it has limitations due to its
administrative nature. Specifically, the data only include information on
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prescription medications that are processed and ultimately billed to the MPD plan.
This means that in addition to providing no information on over-the-counter
medication use, this data source also does not provide information on prescription
medications received by beneficiaries but not billed to MPD plans. Particularly
important for this study of PIMs, benzodiazepines, barbiturates, and many
gabapentinoids were excluded from coverage by MPD until to the implementation
of the Patient Protection and Affordable Care Act in 2013.119 The sharp increase
in PIM use observed from 2012-2013 may reflect this phenomenon. Indeed, the
literature has shown that many beneficiaries paid out-of-pocket and continued to
receive these medications despite their non-coverage or were switched to other
PIMs by their providers.

120,121

Thus, the low prevalence estimates in this study

from 2012 may be due to misclassification due to these medications not appearing
in the administrative claims data.
Additionally, we were not able to include any beneficiaries who are enrolled
in Medicare Part D plans, but receive services through a managed care plan, due
to CMS not receiving administrative claims data on these plans. While these
beneficiaries only represented about 11% of all Part D beneficiaries in 2012, the
proportion of Part D enrollees utilizing Medicare Advantage managed care plans
has increased annually to almost 20% as of 2019.114
The cross-sectional nature of this study precludes it from providing
information on causality because while we are able to assess whether participants
had an ADRD diagnosis before the start of the study, we cannot ascertain PIM use
prior to 2012. Nevertheless, it is intriguing that PIM use was so much more
prevalent among beneficiaries with ADRD. As noted, those with ADRD were older
and had more health conditions than those without ADRD, so these beneficiaries
may have been using more medications in general and thus been more likely to
use a PIM. On the other hand, it may be that use of certain medications by
beneficiaries before they developed ADRD may have contributed to its
development. The high prevalence of Cog-Beers and ADS PIM use is a striking
finding, given that the medications in these criteria have significant evidence
suggesting that their use can worsen cognitive function.122,123
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Overall, the wide range of prevalence estimates shown in this study
supports the need for a more targeted definition of PIM use, both for research
purposes and clinical use.
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2.3.5 Tables and Figures
Table 2.3.1. Included Beneficiaries
Year
2012
2013
2014
2015
2016

Entire sample, n
1,337,741
1,385,329
1,423,479
1,452,823
1,467,344

Included beneficiaries, n
459,773
568,326
603,925
642,936
685,531

%
34.37
41.02
42.43
44.25
46.72

Table 2.3.2. Beneficiary Characteristics in 2012
Total
n = 459773

ADRD
n = 37272

No ADRD
n = 422501

Demographics
Age, mean (SD)
74.79 (7.38)
82.02 (7.55)
74.16 (7.02)
Female, n (%)
273296 (59.44)
24354 (65.34)
248942 (58.92)
Nonwhite race, n (%)
42510 (9.25)
3387 (9.09)
39123 (9.26)
Comorbidities, n (%)
AMI
3318 (0.72)
597 (1.6)
2721 (0.64)
Anxiety
39355 (8.56)
7046 (18.9)
32309 (7.65)
Atrial fibrillation
45071 (9.8)
6255 (16.78)
38816 (9.19)
Bipolar disorder
4064 (0.88)
1305 (3.5)
2759 (0.65)
Depression
53079 (11.54)
11700 (31.39)
41379 (9.79)
Diabetes
122496 (26.64)
11252 (30.19)
111244 (26.33)
Hyperlipidemia
252316 (54.88)
19838 (53.22)
232478 (55.02)
Hypertension
290300 (63.14)
27956 (75.01)
262344 (62.09)
Stroke
16195 (3.52)
4146 (11.12)
12049 (2.85)
ADRD: Alzheimer's disease and related dementias; AMI: acute myocardial infarction
All group differences significant at p < 0.0001
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Table 2.3.3. Odds of PIM Use

Age
Female
White
Year
2013
2014
2015
2016
Region
Midwest
South
West
Entitlement reason
DIB
ESRD
DIB & ESRD
Comorbidities
ADRD
Anxiety
Bipolar disorder
Depression

Beers 2012
0.999 (0.999-1)
1.153 (1.144-1.161)
0.886 (0.877-0.896)

Cog-Beers
1.002 (1.001-1.002)
1.518 (1.506-1.53)
0.773 (0.763-0.782)

ADS
1.009 (1.008-1.009)
1.5 (1.488-1.513)
0.863 (0.852-0.874)

1.224 (1.217-1.231)
1.132 (1.125-1.138)
1.052 (1.046-1.059)
0.984 (0.978-0.991)

1.423 (1.414-1.432)
1.306 (1.298-1.315)
1.233 (1.224-1.241)
1.176 (1.168-1.185)

1.255 (1.246-1.264)
1.159 (1.15-1.167)
1.114 (1.106-1.122)
1.096 (1.088-1.105)

1.038 (1.027-1.049)
1.41 (1.397-1.424)
1.095 (1.082-1.107)

0.952 (0.941-0.963)
1.23 (1.217-1.243)
1.049 (1.036-1.062)

1.026 (1.014-1.039)
1.245 (1.232-1.259)
0.997 (0.984-1.01)

0.647 (0.306-1.367)
1.348 (0.857-2.119)
2.505 (1.005-6.244)

1.572 (0.538-4.596)
1.533 (0.861-2.729)
2.436 (1.012-5.864)

1.742 (0.622-4.88)
1.264 (0.69-2.314)
4.073 (1.739-9.544)

1.26 (1.247-1.273)
2.011 (1.994-2.028)
1.809 (1.76-1.86)
1.513 (1.502-1.524)

1.458 (1.442-1.474)
2.275 (2.256-2.295)
2.024 (1.969-2.08)
1.676 (1.663-1.689)

1.467 (1.45-1.483)
1.894 (1.877-1.911)
1.872 (1.821-1.924)
1.639 (1.626-1.652)

Cog-Beers: medications considered potentially inappropriate for individuals with dementia according to Beers 2012
criteria; ADS: anticholinergic drug scale; DIB: disability insurance benefit; ESRD: end-stage renal disease; ADRD:
Alzheimer's disease and related dementias
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Figure 2.3.1. Period Prevalence of PIM Use, 2012-2016
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2.3.6 Code Blocks
Code Block 2.3.1. Logistic Regression on PIM Use
ods exclude ObStats(persist);
title 'Logistic Regression on Beers 2012';
proc genmod data=usramart.cms_finalpimprev_20200329 desc;
class beers2012(ref="0") alzh_demen_yn(ref="0")
bene_enrollmt_ref_yr(ref="2012") female(ref="0") white(ref="1") region(ref="1")
entlmt_rsn_curr(ref="0")
anxi_medicare_yn(ref="0") bipl_medicare_yn(ref="0")
depression_yn(ref="0") bene_id;
model beers2012 = alzh_demen_yn bene_enrollmt_ref_yr female white region
entlmt_rsn_curr age anxi_medicare_yn bipl_medicare_yn depression_yn / d=bin link=logit
cl;
repeated subject=bene_id / type=un;
estimate 'ADRD Effect' alzh_demen_yn 1 -1 /exp;
estimate '2013 Year Effect' bene_enrollmt_ref_yr 1 0 0 0 -1 /exp;
estimate '2014 Year Effect' bene_enrollmt_ref_yr 0 1 0 0 -1 /exp;
estimate '2015 Year Effect' bene_enrollmt_ref_yr 0 0 1 0 -1 /exp;
estimate '2016 Year Effect' bene_enrollmt_ref_yr 0 0 0 1 -1 /exp;
estimate 'Female Effect' female 1 -1 /exp;
estimate 'White Effect' white 1 -1 /exp;
estimate 'Midwest Region Effect' region 1 0 0 -1 /exp;
estimate 'South Region Effect' region 0 1 0 -1 /exp;
estimate 'West Region Effect' region 0 0 1 -1 /exp;
estimate 'DIB Effect' entlmt_rsn_curr 1 0 0 -1 /exp;
estimate 'ESRD Effect' entlmt_rsn_curr 0 1 0 -1 /exp;
estimate 'DIB w/ESRD Effect' entlmt_rsn_curr 0 0 1 -1 /exp;
estimate 'Anxiety Effect' anxi_medicare_yn 1 -1 /exp;
estimate 'Bipolar Effect' bipl_medicare_yn 1 -1 /exp;
estimate 'Depression Effect' depression_yn 1 -1 /exp;
run; quit; title;
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2.4

Discussion

The studies in this section have demonstrated that the prevalence of PIM use
among older adults in the United States can range from 3.1% to 79.2% depending
on the definition of PIM use, whether the individual is cognitively impaired, and the
data source used to ascertain estimates. PIM prevalence was highest when
defined using criteria unspecific to disease state with low cut-offs, and lowest when
more stringent definitions were applied. While this range is large, it highlights the
the necessity of a clear definition for PIM use if it is to be used as a tool to prevent
cognitive decline.
When the most general tools (such as the Beers criteria) are used to define
PIM use, prevalence estimates are highest. According to self-report by participants
at ADCs, prevalence of PIM use when defined as use of any medication in the
2015 Beers Criteria was 28.9% and 35.7% among individuals without and with
cognitive impairment respectively. However, when this same definition of PIM use
was applied to a population of older adults with Medicare Part D and ascertained
from administrative claims data, prevalence was significantly higher: 40.6-45.7%
among individuals without ADRD and 52.0-57.65 among individuals diagnosed
with ADRD.
This difference may be explained by numerous factors. First, data in NACC
is provided by self-report only annually, and participants are asked to recall
medications used in the last two weeks. While this data can provide important
information on over-the-counter medication use that would not be included in
administrative prescription claims, it also excludes medications that participants do
not recall using, use sparingly, or used outside the requested time range.
Additionally, the extent and type of exposure misclassification varies
between the two data sources. In the survey data, the false positive rate is likely
to be low because participants have no incentive to falsely report using a
medication. However, the false negative rate may be higher due to lack of
recollection, misunderstanding of what medications should be reported, and the
previously discussed time constraints. In the administrative claims data, however,
the misclassification issues are the opposite. The false positive rate has the
43

potentially to be quite high if medications are billed to the insurance plan, but
beneficiaries are not using them. Some studies suggest that this phenomenon is
quite common, especially due to financial concerns or memory problems.124,125
Prescription administrative claims data also have the potential for false negatives,
as the only medications that are captured are those that are billed to the insurance
plan and ultimately covered, and claims exclude almost all non-prescription
medications.126,127
In both studies, regardless of the PIM definition used, PIM prevalence was
higher among individuals who were not cognitively normal. This finding is in line
with other estimates globally,40,128 and is concerning given the available evidence
linking many medications in these appropriateness tools to negative cognitive
outcomes. However, due to the cross-sectional nature of the studies in this section,
it is not possible to determine whether use of these PIMs causes cognitive
abnormalities. While the presence of ADRD was associated with between 1.26 –
1.47 times the odds of PIM use in the second study presented in this section, other
factors including psychiatric comorbidities and frailty (as measured by original
Medicare entitlement reasons) were more highly associated with potentially
inappropriate medication use. Thus, it is possible that the relationship between
ADRD and PIM use is confounded by both measured and unmeasured factors.
The wide range of prevalence estimates presented in this section supports
the need for a more targeted definition of PIM use, both for research purposes and
clinical use. For researchers, depending on whether PIM use is used as an
exposure or an outcome, the variability in its prevalence can have dire
consequences on research findings. In clinical practice, both patients and their
providers should have access to a validated tool that can identify potentially
inappropriate medications when concerns about negative impacts on cognition
reign supreme.
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3

TARGETING MEDICATION APPROPRIATENESS MEASURES TO
COGNITION

3.1

Introduction

The previous section highlighted the near ubiquity of potentially inappropriate
medication (PIM) use in older adults, yet at the same time underlined the variance
in how different definitions of PIM use can lead to a lack of clinical and academic
utility. We showed that the more stringent definitions of PIM use result in lower
prevalence estimates, but regardless of how one defines PIM use, individuals with
cognitive impairment are more highly afflicted by its use. Unfortunately, the crosssectional nature of the previous studies prevents them from providing inference
into the potential causal relationship between PIM use and cognition.
At the outset of this work, we summarized results from nearly twenty
different studies that investigated the link between cognitive decline and eight
different medication appropriateness assessment tools. We showed that while
some studies professed to find evidence for a link between the studied tool and
proposed measure of cognitive decline, other studies of those same tools failed to
find such evidence. This lack of consistency occurred whether the studied tool was
more general or specific to certain medication classes such as anticholinergics or
sedatives. Notably, every one of these studies utilized an observational study
design in which the strongest control for confounding was statistical adjustment by
adding measured covariates to regressions. Thus, despite the questions asked by
these researchers being largely causal in nature, they have not made use of the
many extensions to the standard statistical language that make causal analysis of
observational data possible.
Since the nine "aspects of association" were proposed by Bradford Hill in
1965,129 causal analysis has been revolutionized.130 Statisticians, epidemiologists,
economists, and researchers from many other disciplines now rely upon recent
advances in counterfactual analysis, nonparametric structural equations, graphical
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models, and combinations of these techniques131 to solve such causal problems
as we find ourselves concerned with in this work.
Due to the lack of consensus regarding the relationship between PIM use
and cognition and the lack of research using advanced techniques to resolve many
shortcomings to study design, we will undertake to provide evidence that answers
the following question: "Does potentially inappropriate medication use, as defined
by certain clinically meaningful explicit criteria, increase the risk and/or rate of
cognitive decline?" In this section, we will explore different PIM assessment tools
including both general criteria and those purporting to pertain specifically to
cognitive outcomes. In addition to exploring the effect of different definitions of PIM
use, we will also utilize varying measurements of cognitive decline in various data
sources. This section will build upon the previous by moving forward from simply
estimating how many people would be considered PIM users, to investigating
characteristics of PIM users and comparing them to PIM nonusers to determine if
there are differences in either the incidence or rate of cognitive decline. Each study
will incorporate modern statistical and study design techniques in an attempt to
limit the interference of confounding and arrive upon a more accurate and precise
conclusion.
The first study in this section will examine one of the most general PIM use
tools, the 2015 Beers criteria. However, instead of including only the first list of
medications deemed potentially inappropriate in all older adults (as most studies
utilizing do40), this study will examine the effect of potentially inappropriate drugdisease and drug-drug interactions therein in an attempt to determine whether
more patient-specific factors are more predictive of cognitive decline. This study is
conducted in a national population of older adults with employer-sponsored health
insurance, using administrative prescription claims. It utilizes standardized survival
curves and a new-user study design to improve causal inference.
The next study will make use of the same longitudinal cohort of patients as
the first prevalence study from Section Two (namely, data from NACC), but will
implement a new-user design into the retrospective cohort study and apply inverse
probability for treatment and censoring weights will remove much of the selection
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bias traditionally associated with studies in this unique population. In addition to
investigating general criteria such as Beers and STOPP, it will also consider the
sub-lists within each of these criteria that specify certain medications as
inappropriate for those with dementia or cognitive impairment. We will apply this
definition to individuals with and without cognitive impairment at baseline and
determine whether there are any clinically significant declines in a specific
measure of cognitive performance over approximately one year.
The last study in this section will again employ the Medicare Part D
administrative prescription claims data from CMS to estimate whether there the
association seen between cognitive decline PIM use defined as medications
deemed inappropriate in the context of dementia by the Beers Criteria is doserelated. This study will use different modeling techniques in an attempt to remove
confounding by indication, a common culprit of confounding in studies of PIM use
and cognition.
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3.2

Drug-drug interactions modify dementia risk associated with

potentially inappropriate medication use: a retrospective cohort study

3.2.1 Introduction
Although dementia is a major cause of death, disability, and dependency among
older adults worldwide132, it remains the only one of the top ten causes of death
without an effective treatment or cure133. As the scientific community continues to
make advances in identifying potential therapeutic targets, preventing or delaying
dementia has become increasingly important134. A novel modifiable risk factor for
dementia is the use of inappropriate medications by older adults. While evidence
linking the use of various medications to increased risk for dementia is mounting,
it can be conflicting. Studies have been published both implicating and exonerating
medications

including

anticholinergics,

antidepressants,

antipsychotics,

benzodiazepines, and proton-pump inhibitors for their links to dementia123,135–139.
Deprescribing is the process of removing or reducing the doses of
inappropriate medications (PIMs)140. However, it can be difficult for prescribers to
synthesize the vast literature in order to practice evidence-based deprescribing
because of constraints on time, resources, and patient engagement141,142. Thus,
many healthcare providers look to tools developed by professional organizations
to guide deprescribing decisions. The American Geriatrics Society manages one
such resource: the Beers criteria. Originally developed in 1991, the current Beers
criteria comprise a list of PIMs that should be avoided in all adults aged 65 years
and older, and also lists of medications that may be inappropriate as a result of
their interactions with other medications (known henceforth as potentially
inappropriate drug-drug interactions, or PI-DDIs)43. A PI-DDI may or may not
include a medication otherwise considered to be potentially inappropriate when
used alone. Thus, PI-DDIs are more patient-specific than PIMs because they take
into consideration the entire medication regime. While the Beers criteria can serve
as a helpful guide when deprescribing, it remains unclear whether deprescribing
PIMs reduces the risk for incident dementia.
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A number of studies have used the Beers criteria to identify PIMs and
directly assess their link with cognition in non-demented individuals and those with
cognitive impairment, but none have used the more patient-specific PI-DDI criteria
as a potential cause of reduced cognition.40 The American Geriatrics Society
stressed that these PI-DDIs were “highly associated with harmful outcomes in
older adults,”42 and even highlighted the use of multiple anticholinergic
medications as a PI-DDI due the increased risk of cognitive decline.69 However,
many of the other PI-DDIs can increase the risk of falls, which have also been
shown to increase the rate of cognitive decline.143 Targeting PI-DDIs in
deprescribing efforts is a more patient-centered approach as it takes into account
individual medication regimens, and thus PI-DDIs are an important component of
PIM use that requires studying.
The purpose of this study was to investigate whether use of PIMs in the
Beers criteria was associated with an increased risk of dementia in older adults. In
addition to use of any medication in the Beers criteria, use of specific classes of
medications (including those acting on the central nervous, endocrine,
cardiovascular, and gastrointestinal systems, as well as analgesics and strong
anticholinergic medications), and PI-DDIs were also investigated.

3.2.2 Methods
3.2.2.1 Study Population and Design
This study was a retrospective cohort analysis of patients enrolled in employersponsored private health plans from 2009-2017. Data were obtained from the
Truven

Health

MarketScan

Commercial

and

Medicare

Supplemental

Databases.144 Both databases are collected by Truven Health from employers and
health plans and consist of service-level claims throughout the continuum of care,
including physician office visits, hospital stays, and pharmacy services for a
combined total of nearly 240 million covered lives serviced by over 350 unique
carriers. Individuals in the Medicare Supplemental Database are generally retirees
with Medicare supplemental insurance paid by employers.145
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The data that support the findings of this study are available from Truven
Health Analytics,144 which were used under license for the current study.
Restrictions apply to the availability of these data, and so they are not publicly
available. Data are however available from the authors upon reasonable request
and with permission of Truven Health Analytics.
This retrospective cohort study investigated the association between PIM
use and incident dementia diagnosis (see Figure 3.2.1). Patients ≥ 65 years old
were included if they had at least three medical claims and no dementia diagnoses
during the three-year run-in period, and at least one prescription claim in the last
six months of the run-in period. A three-year run-in period was chosen based on
validated algorithms for identifying dementia in administrative claims databases.146
3.2.2.2 Measurements
The exposure in this study was PIM use, defined as any claim for a PIM in the last
six months of the run-in period. Exposure to PIMs was considered as the
presence/absence of 1) any PIM, 2) specific classes of PIMs, and 3) PI-DDIs, as
specified in Tables 2 and 5 of the 2015 updated Beers criteria,42 with some
exceptions described in Table 3.2.1. Specific PIM classes included strong
anticholinergics, cardiovascular agents, central nervous system (CNS-active)
agents, endocrine agents, gastrointestinal agents, and analgesic agents. Ten PIDDIs are described in the Beers Criteria, of which four contain at least one agent
included as a PIM when used alone (see Table 3.2.2). PI-DDIs include the use of:
angiotensin-converting enzyme inhibitors (ACEi) with potassium-sparing diuretics,
more than one anticholinergic medication, more than two CNS-active medications,
corticosteroids with nonsteroidal anti-inflammatory drugs (NSAIDs), lithium with
either an ACEi or loop diuretic, peripheral alpha-1 blockers (Pα1B) with a loop
diuretic, theophylline with cimetidine, and warfarin with either amiodarone or
NSAIDs.
The outcome was incident dementia diagnosis, which was defined using
International Statistical Classification of Diseases and Related Health Problems
(ICD) diagnosis codes and/or presence of a prescription claim for a cognitionenhancing medication. Previously validated ICD-9 codes for dementia subtypes
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were used and cross-referenced to ICD-10 codes using General Equivalence
Mappings (GEMs) as shown in Supplementary Table 3.2.1.147 Cognitionenhancing medications were identified using the Generic Product Identifier
(GPI)148 secondary classification of “antidementia agents” and included the
following single and combination agents: acetylcarnitine, donepezil, galantamine,
memantine, rivastigmine, and tacrine. Follow-up began on the index date, defined
as the first day following the satisfied run-in period. Time-to-event was defined as
the interval between the index date and the first claim with a dementia diagnosis
or prescription; patients without a dementia diagnosis were censored on the earlier
date of disenrollment from the health plan or December 31, 2017 (see Figure
3.2.1).
Covariates were selected using a directed acyclic graph (see Figure 3.2.2)
and included age and sex, along with the number of prescription claims for distinct
medications (identified using the first eight digits of the GPI) in the six months prior
to the index date as a measure of polypharmacy. Additionally, the following set of
comorbidities were measured using the Clinical Classification System or ICD
diagnosis codes in the year prior to the index date: atherosclerotic cardiovascular
disease (ASCVD), delirium, depression, diabetes, fractures, hypertension,
insomnia, Parkinson disease, seizures, and substance use disorder.
3.2.2.3 Statistical Analysis
Descriptive statistics were used to compare exposed and unexposed groups,
including chi-squared tests, Wilcoxon-Mann-Whitney tests, and Student’s t-tests.
For each exposure, a Cox proportional hazard regression model was used
to calculate hazard ratios (HR) and corresponding 95% confidence intervals (CI)
for the association between the different exposures and dementia. Models were
adjusted for sex and age (centered at the mean of 74.2 years), in addition to
comorbidities and the baseline medication count (truncated at the top 1%). To
determine whether the association of PIM use with hazard of dementia diagnosis
was modified by PI-DDIs, dummy indicators were specified to denote whether the
patient used any PIM without PI-DDI (P1D0), any PIM with PI-DDI (P1D1), or no
PIMs with PI-DDI (P0D1). Corresponding stratum-specific HRs were estimated with
51

the reference group as no PIM use without PI-DDIs (P0D0). Corresponding SAS
code is available in Code Block 3.2.1.
To aid in the interpretation of HRs149 and to visualize the difference in risk,
standardized survival curves were plotted by averaging over all observed patientspecific survival curves. These curves were generated with the SAS macro
program %ADJSURV, which calculates the direct adjusted survival probabilities
based on regular and stratified Cox models.150 Figures were created using the SAS
code found in Code Block 3.2.2.
Analyses of specific PIM classes followed the same procedures, except
that any specific PIM class with less than 1% prevalence was excluded to avoid
bias introduced due to sparse data.151,152
In addition, two sensitivity analyses were performed. The first modified the
definition of PIM use to exclude use in the six months prior to the index date, since
some PIMs may be used to treat prodromal symptoms of dementia153–155 which
could introduce protopathic bias. The second modified the outcome definition to
exclude receipt of cognition-enhancing medications to avoid misclassifying
patients who may have received these medications for diagnoses other than
dementia (for example, off-label use for psychiatric disorders or traumatic brain
injury156,157).
All statistical analyses were conducted in SAS Enterprise Guide.158

3.2.3 Results
3.2.3.1 Study Population
A total of 2,380,986 patients were included in this study, 42.8% of whom used at
least one PIM in the six months prior to the index date (Table 3.2.3). Patients were
an average of about 74 years old at the index date, and the majority were female.
The most prevalent comorbidities identified during the last year of the 3-year runin period were hypertension, ASCVD, and diabetes, with each being more
prevalent among PIM users than non-users. PIM users had almost twice as many
prescription claims for distinct medications in the six months prior to the index date
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than non-users (median [IQR] 6 [4-9] and 3 [2-5] for users and non-users
respectively), and also had more PI-DDIs than non-users (13.3% versus 0.4%).
3.2.3.2 PIM Use and Dementia
Patients contributed a median of 26.3 person-months (range 0.03 to 73 months)
of time at risk. PIM users contributed more time at risk (29.4 vs 24.3 personmonths; p<0.001) compared to non-users. During follow-up, 182,929 patients were
newly diagnosed with dementia. A diagnosis of dementia “not otherwise specified”
was the most common first diagnosis of dementia (66.5%), followed by receipt of
a cognition-enhancing prescription (18.1%) and a diagnosis of Alzheimer’s
dementia (11.8%). Supplementary Table 3.2.1 describes the distribution of
dementia subtypes identified.
Dementia was diagnosed at a higher rate among PIM users than nonusers
in unadjusted analyses (HR [95% CI] 1.17 [1.16-1.18]), but this association moved
to the null after adjusting for known and measurable confounders (0.99 [0.98,
1.00]; see Figure 3.2.3). While use of any PIM was not significantly associated with
dementia diagnosis, a significant association between use of two specific PIM
medication classes and dementia was observed: CNS-active medications (1.28
[1.27-1.30]) and strongly anticholinergic medications (1.17 [1.15-1.19]). Use of
gastrointestinal PIMs (defined as use of metoclopramide or proton pump inhibitors)
was associated with a lower rate of dementia diagnosis compared to those who do
not use these PIMs (0.79 [0.78-0.81]). Only one PI-DDI was associated with an
increased hazard for dementia: >2 CNS-active medications (1.36 [1.32-1.40]). It is
notable that only 8% of CNS-active PIM users used >2 CNS-active PIMs, and only
9% of anticholinergic PIM users used >1 anticholinergic (see Figure 3.2.3). The
associations between dementia and use of >1 anticholinergic (0.95 [0.93-0.98),
corticosteroids with NSAIDs (0.93 [0.88-0.99), and warfarin with amiodarone (0.92
[0.86-0.99]) were near the null.
There was a statistically significant interaction between PIM use and PIDDIs. Neither those in the P1D0 group nor the P0D1 group had increased hazards
of dementia (0.99 [0.98-1.00] and 0.84 [0.75-0.94] respectively). However, those
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in the P1D1 group had an increased hazard of dementia (1.30 [1.17-1.46]). These
HRs reference patients in the P0D0 group; see Figure 3.2.4.
3.2.3.3 Sensitivity Analyses
The primary exposure was also defined as any use of a PIM during the run-in
period, excluding the most recent 6 months to remove users who may have been
treating prodromal dementia symptoms159. This exposure definition identified
65.8% of patients as PIM users, and increased the effect sizes for most hazard
ratios compared to the original analysis.
Additionally, when receipt of cognition-enhancing prescription medications
was excluded from the dementia outcome, the number of dementia cases
decreased by about 20% to 146,487. There were no significant changes in effect
sizes for any of the exposures, except the use of ACEi with potassium-sparing
diuretics, which decreased to a HR of 0.73 (95% CI 0.67-0.80; see Supplementary
Tables).

3.2.4 Discussion
The results from this retrospective cohort study corroborate existing evidence
implicating potentially inappropriate CNS-active and anticholinergic medications in
an increased hazard for dementia. In addition, this study demonstrates that the
use of PI-DDIs as identified in the Beers Criteria modify the relationship between
PIM use and dementia, indicating that PIM users with PI-DDIs have the highest
rate of dementia diagnosis. To our knowledge, this is the first study to consider
cognitive outcomes related to both PIMs and PI-DDIs in the Beers Criteria. The
use of patient-specific measures such as PI-DDIs is relatively new in the 28-year
history of the Beers Criteria. The AGS acknowledged the need to add more patientcentered criteria to the tool in 2015, and went so far as to publish a companion
article alongside the 2015 update wherein clinicians and payers were encouraged
to take patient desires and attributes into consideration when applying the Beers
Criteria in practice160.
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The finding that use of any PIM as identified in the Beers Criteria is not
associated with an increased risk for dementia diagnosis, while use of any PIM
with a PI-DDI is associated with an increased risk is a novel finding, and in line
with AGS’s recommendation that deprescribing based on the Beers Criteria should
be more patient-centered. Such results may be useful for healthcare providers who
are in need of evidence in order to prioritize optimization of medication regimens.
In fact, physicians report that one of the greatest barriers to deprescribing is
agreeability of patients and caregivers10. The ability to not only use the Beers
Criteria as a tool to identify PIMs, but also to rank necessary deprescribing
decisions in order of their importance to preventing future cognitive decline may
make medication appropriateness tools such as the Beers Criteria even more
valuable for clinicians when working with their patients.
However, the Beers Criteria are not the only medication appropriateness
tool available to clinicians. While clinicians in North America rely primarily on the
Beers Criteria, several other evidence-based tools are used in practices in Europe
and around the world. These tools vary based on whether they include many
different classes of medication as in the Beers Criteria (such as the STARTSTOPP Criteria80 or the Drug Burden Index58) or focus on specific classes of
medications (including the Anticholinergic Drug Scale47, and Sedative Load55).
While these other PIM measurement tools are not generally used in practice in the
United States, they have been more well-studied than the Beers Criteria for their
link to cognition50,53,58,69,71. Still, the Beers Criteria remains the only one of these
tools to consider PI-DDIs, which appear to modify the association between PIM
use and dementia.
The results of this study also demonstrate that PI-DDIs may have
heterogenous effects with regard to dementia hazard. Notably, while PIM users
with PI-DDIs had an increased hazard of dementia, PIM non-users with PI-DDIs
appeared to have a decreased hazard of dementia. Although we have less
confidence in this finding due to the small sample size (only 0.4% of PIM non-users
also had a PI-DDI), it is notable that the most common PI-DDI among PIM nonusers was the use of an ACEi with a potassium-sparing diuretic (89.9%, results not

55

shown). The lack of variability in PI-DDIs among PIM-nonusers may indicate that
the estimate is not measuring PI-DDIs in PIM non-users, but rather the effect of a
particular type of antihypertensive therapy among PIM non-users. Given that such
therapy has been associated with a decreased dementia risk161,162, further studies
able to adjust for blood pressure should be conducted.
It is possible that the definition of exposure to PIMs as use within 6 months
of the index date may have meant that the PIMs were being used to treat prodromal
symptoms of dementia159, potentially indicating reverse causation. Despite the fact
that the median follow-up time was 26.3 months (indicating that most patients did
not obtain a dementia diagnosis or prescription for at least two years after this
exposure) a sensitivity analysis was performed that excluded the most recent 6
months of PIM use from the exposure definition and found it did not appreciably
change the results. These findings are consistent with other available literature123,
indicating that defining a PIM use exposure as use within six months of the index
date does not introduce reverse causation. We also stress that the purpose of this
analysis was to study dementia diagnosis, not whether the medications used in
this study are associated with changes in the underlying neuropathology.
Of all cases of dementia identified, 18.1% were identified at least in part
through receipt of cognition-enhancing prescription medications. For 95.9% of
those patients, use of such a medication was the sole method of dementia
diagnosis. Thus, these patients received a prescription for a cognition-enhancing
medication before they received a diagnosis for dementia. This finding could occur
because these patients did not meet the qualifications for a dementia diagnosis
but nevertheless were experiencing cognitive impairment that warranted
medication treatment, or because of anomalies in the administrative data source.
Nevertheless, to determine whether these patients were differentially affected by
PIM use, a sensitivity analysis was performed that excluded these patients from
the analysis. Again, the results did not change appreciably, lending confidence to
the use of this novel outcome definition.
Despite our efforts to reduce confounding by verifying the sensitivity of both
our exposure and outcome measurements, some findings in this study warrant
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consideration. While use of strong anticholinergic prescriptions was associated
with an increased rate of dementia diagnosis, use of more than one strong
anticholinergic was not. It may be that the 10% of anticholinergic users who used
multiple strong anticholinergic prescriptions were substantially different than those
who only used one in ways that our data could not detect. For instance, if providers
are aware of the strong evidence base linking anticholinergics to dementia, they
may reserve the use of multiple anticholinergics to patients who they feel are at a
much lower risk for reasons such as no family history of cognitive impairment, no
obesity or tobacco use, or higher level of education. These factors cannot be
assessed in the data, indicating there may be some residual confounding.
Additionally, use of gastrointestinal PIMs (defined as use of metoclopramide
or proton pump inhibitors [PPIs]) was associated with a lower rate of dementia
diagnosis compared to those who do not use these PIMs. The overwhelming
majority of these PIM users were identified based on receipt of PPI prescription
rather than of metoclopramide. The relationship between PPIs and dementia is
unclear, and studies have been published suggesting that PPIs both increase and
decrease the risk136,137,163,164, though major organizations still recommend their
deprescription in older adults33. In this study, only PPIs obtained through private
prescription healthcare insurance can be measured, but because many PPIs are
currently available without a prescription it is likely that not all true PPI users are
identified. Given that PPI use is on the rise in the older adult population165, this
finding warrants further consideration. This limitation is true of any medications that
are not routinely paid for by prescription health insurance (including over-thecounter and supplemental medications that may be used to improve cognition).
The nature of the data source in this study also affects generalizability of
these findings. Patients in this study receive healthcare benefits supplemental to
Medicare, which has declined substantially in the US, with only approximately 28%
of retirees receiving supplemental healthcare insurance coverage through their
employers in 2013

118

. Individuals who receive retiree health benefits are more

likely to be government employees, those with higher wages, and those in large
unionized firms. In addition, most of the employers who provide data to Truven
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Health are medium or large firms, so retirees of smaller firms, or those with lower
wages are likely underrepresented in this data. However, the large size of this data
offers a significant advantage when studying dementia due to its ability to capture
many cases.
Overall, this study supports the current body of literature that implicates
anticholinergic and CNS-active medications in cognitive decline and adds the
nuance that users of any PIM who also have a PI-DDIs are at a higher risk for
dementia than those who use PIMs without PI-DDIs. Thus, the Beers Criteria can
be a valuable tool to optimize medication regimens with the goal of reducing
dementia risk by incorporating patient-specific factors such as drug-drug
interactions instead of only considering use of PIMs. Further research should
utilize different data sources to reduce residual confounding, especially due to
factors unmeasured in this study, and explore other medication appropriateness
tools.
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3.2.5 Tables and Figures
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Table 3.2.1. Exceptions to Potentially Inappropriate Medication Definition
Exception
Medications
Reasoning
Excluded
Nitrofurantoin
No data on creatinine clearance
Excluded
Diltiazem, verapamil
No data on ejection fraction
Ergoloid mesylates, isoxuprine, mineral
Rarely used in United States, removed from 2019
Excluded
oil
Beers’ Criteria
Included
Any PIM qualified as only potentially
Cannot differentiate between treatment patterns or
unconditionally
inappropriate for first-line therapy
trajectories
Androgens, desmopressin,
Cannot identify clinical characteristics providing
Included
metoclopramide, non-steroidal antiexceptions
unconditionally
inflammatory drugs, proton-pump
inhibitors
Table 3.2.2. Potentially Inappropriate Drug-Drug Interactions
Potentially inappropriate medications
Anticholinergic
Antidepressant
Central nervous system-active
Antipsychotics
Benzodiazepine
Nonsteroidal anti-inflammatory drug
Peripheral alpha blocker
Amiodarone

Appropriate Medications
Angiotensin converting enzyme inhibitor
Amiloride
Triamterene
Corticosteroid
Lithium
Loop diuretic
Opioid
Theophylline
Warfarin
Cimetidine

Table 3.2.3. Baseline Characteristics

Total
n=2,380,986

PIMa Users
n=1,018,427
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Demographics
Age, mean (SD)
74.16 (7.68)
74.30 (7.67)
Female, n (%)
1,299,996 (54.60)
585,229 (57.46)
Comorbidities, n (%)
ASCVDb
725,183 (30.46)
349,065 (34.27)
Delirium
2,189 (0.09)
1,403 (0.14)
Depression
150,779 (6.33)
94,829 (9.31)
Diabetes
701,719 (29.47)
322,276 (31.64)
Fractures
328,312 (13.79)
155,892 (15.31)
Hypertension
1,457,950 (61.23)
652,059 (64.03)
Insomnia
11,812 (0.50)
7,285 (0.72)
Parkinson’s Disease
18,534 (0.78)
9,212 (0.90)
Seizures
26,233 (1.10)
13,265 (1.30)
Substance Use Disorder
24,277 (1.02)
13,649 (1.34)
Medication Use
Distinct RX, median (IQR)
4 (2-7)
6 (4-9)
Any PI-DDI, n (%)
139,924 (5.88)
135,066 (13.26)
a
b
potentially inappropriate medication; atherosclerotic cardiovascular disease
All group differences statistically significantly different at p < 0.001.

PIM Non-users
n=1,362,559
74.05 (7.69)
714,767 (52.46)
376,118 (27.60)
786 (0.06)
55,950 (4.11)
379,443 (27.85)
172,420 (12.65)
805,891 (59.15)
4,527 (0.33)
9,322 (0.68)
12,968 (0.95)
10,628 (0.78)
3 (2-5)
4,858 (0.36)

Figure 3.2.1. Study Design
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Figure 3.2.2. Directed Acyclic Graph for PIM Use on Dementia
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Figure 3.2.3. Associations between PIMs and Dementia
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Figure 3.2.4. Standardized Time-to-Event Curves
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3.2.6 Supplementary Data
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Supplementary Table 3.2.1. Dementia Diagnosis Codes and Distribution
Subtype
ICD-9 Codes
ICD-10 Codes
AD
331.0
G300, G301, G308, G309
Vascular
290.40-290.43
F015.0, F015.1
331.82 or (332.0 and
G318.3 or (G020/G214 and
Lewy body
331.0)
G300/G301/G308/G309)
Frontotemporal
331.1, 331.11, 331.19
G310.9, G310.1
Alcohol-induced
291.2
F102.7
A8100, A8101, A8109, F1327, F1397,
046.11, 046.19, 292.82,
Other
F1817, F1827, F1897, F1917, F1927,
333.4
F1997, G10
290.0-290.3, 290.9,
Not otherwise
F0280, F0281, F0390, F0391, F061,
294.1-294.21, 294.8,
specified
F068, G311, R4181, R54
331.2, 797
Prescription
---

First, n
21,593
10,001

Sole, n
15,859
8,657

2,156

1,656

721
421

520
365

255

236

121,694

113,127

33,159

31,788

Supplementary Table 3.2.2. Sensitivity Analyses
Analysis,
Hazard Ratio [95% CI]
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Original

Exclude recent PIM use

Overall
Any PI-DDI
Any PIM
Any PIM + Any PI-DDI

Exclude prescriptions in
diagnosis

0.84 [0.75, 0.94]
0.99 [0.98, 1.00]
1.30 [1.16, 1.45]

1.19 [1.17, 1.20]
1.09 [1.08, 1.10]
1.34 [1.31, 1.37]

0.79 [0.70, 0.90]
0.97 [0.96, 0.98]
1.37 [1.21, 1.56]

PIM classes
CNS-active
Strong anticholinergic
Endocrine
Analgesic
Cardiovascular
GI

1.28 [1.27, 1.30]
1.17 [1.15, 1.19]
1.00 [0.98, 1.02]
0.98 [0.96, 0.99]
0.97 [0.96, 0.99]
0.79 [0.78, 0.81]

1.24 [1.22, 1.25]
1.13 [1.12, 1.14]
1.08 [1.06, 1.09]
0.97 [0.96, 0.98]
1.06 [1.05, 1.08]
0.93 [0.92, 0.94]

1.30 [1.28, 1.32]
1.16 [1.14, 1.18]
0.97 [0.95, 1.00]
0.95 [0.94, 0.97]
0.99 [0.97, 1.01]
0.77 [0.75, 0.78]

PI-DDIs
>2 CNS
1.36 [1.32, 1.40]
1.37 [1.36, 1.39]
1.37 [1.33, 1.42]
Warfarin-NSAID
1.05 [0.96, 1.15]
1.07 [1.03, 1.11]
1.05 [0.95, 1.17]
ACEi-K sparing diuretic
0.99 [0.98, 1.00]
0.94 [0.90, 0.98]
0.73 [0.67, 0.80]
>1 anticholinergic
0.95 [0.93, 0.98]
1.00 [0.99, 1.01]
0.92 [0.89, 0.95]
Corticosteroid-NSAID
0.93 [0.88, 0.99]
0.92 [0.89, 0.94]
0.90 [0.84, 0.97]
Warfarin-amiodarone
0.92 [0.86, 0.99]
1.02 [0.98, 1.06]
0.96 [0.89, 1.04]
CI: confidence interval; PI-DDI: potentially inappropriate drug-drug interaction; PIM: potentially inappropriate medication;
CNS: central nervous system; GI: gastrointestinal; NSAID: non-steroidal anti-inflammatory drug

3.2.7 Code Blocks
Code Block 3.2.1. Survival Analysis with Standardized Survival Times
/* survival analysis */
proc sort data=usramart.truven; by descending anypim; run;
proc phreg data = usramart.truven;
class anypim(ref="0") anypimdi(ref="0") sex ascvd delirium dep diabetes frac htn insom park sx sud;
model totfu*event(0) = anypim|anypimdi
age_mean_cent sex rxcount_trunc1 ascvd delirium dep diabetes frac htn insom park sx
sud;
hazardratio "Effect of PIM" anypim / diff=ref at(anypimdi=all);
hazardratio "Effect of PIM-DI" anypimdi / diff=ref at(anypim=all);
run;
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/* run macro to generate dataset with standardized survival times */
%ADJSURV(truven_nomiss2, totfu, event, pim_pimdi_inx, age_mean_cent sex rxcount_trunc1 ascvd delirium dep diabetes frac htn insom
park sx sud, 1, outdata);

Code Block 3.2.2. Creation of Standardized Survival Curves by PIM and PI-DDI
Use
data usramart.outdata2;
set outdata;
label surv1="No PIMs or PI-DDIs";
label surv2="PI-DDIs without PIMs";
label surv3="PIMs without PI-DDIs";
label surv4="PIMs with PI-DDIs";
months = time/30;
run;

ods listing gpath='\\file2\amartinez\Dementia\SAS';
ods graphics / imagename="survival" imagefmt=epsi;
proc sgplot data=usramart.outdata2;
series x=months y=surv1 / lineattrs=(pattern=4 color=darkblue);
series x=months y=surv2 / lineattrs=(pattern=1 color=darkblue);
series x=months y=surv3 / lineattrs=(pattern=4 color=darkred);
series x=months y=surv4 / lineattrs=(pattern=1 color=darkred);
yaxis ranges=(0-0.005 0.8-1) values=(0 0.8 0.85 0.9 0.95 1) label="Probability
of Remaining Dementia-Free";
xaxis label="Time (Months)" values=(0 6 12 18 24 30 36 42 48 54 60 66 72 78);
run; quit;
ods graphics off
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3.3

Meaningful measurement matters: potentially inappropriate
medication use and its effect on cognition in older adults

3.3.1 Introduction
The importance of properly managing medication use in older adults is growing,
highlighted by an increased focus on deprescribing, or the process of removing or
reducing the dose of inappropriate medications.166 In fact, over the last five years,
several countries have established national networks aimed at improving the
deprescribing process specifically for the older adult population.167–170 Though
there are many reasons why older adults may need to withdrawal or reduce the
dose of a medication, one growing concern is that certain medications may be
associated with negative cognitive outcomes, including such common medications
as benzodiazepines, antidepressants, and anticholinergic medications.122,171,172
While the research literature is rife with studies of individual medications or
medication classes and their links to cognitive outcomes, it can be difficult for
healthcare providers to maintain accurate and timely knowledge on the everchanging research landscape.
Recognizing that providers need tools to aid in medication therapy
decisions, professional organizations have created and maintained lists of explicit
criteria that identify potentially inappropriate medications (PIMs) for older adults.
In North America, the Beers Criteria43 is widely used, and lists 30 medication
classes that are potentially inappropriate for any adult aged 65 years or older.
Similarly in Europe, the Screening Tool for Older Persons Prescriptions (STOPP)
cites 80 criteria for deprescribing.81 Outside of these explicit lists of criteria, the
concurrent use of five or more medications concurrently (polypharmacy) is often
considered potentially inappropriate regardless of the specific medications used15.
While these tools were developed to improve medication use in older adults, their
use in healthcare practice varies as practitioners attempt to put patients at the
center of care and adapt the tools to each clinical scenario.
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Unfortunately, clinical nuance is often difficult to capture in research
settings, where the lack of a consistent definition of PIM use has led to conflicting
evidence regarding its effect on clinical outcomes40. Currently, all studies using
existing PIM measurement tools to investigate PIM use do so by defining PIM use
as an “ever-never” dichotomous exposure, based on whether study participants
ever use any medication in a given tool. However, new evidence in studies of
specific PIMs (not necessarily defined using PIM measurement tools) suggests
that PIM use may be better-measured when the extent of use by participants is
considered123,135. While this newer evidence is valuable, it can be difficult for
clinical practitioners to stay abreast of every possible medication that may be
linked to negative cognitive outcomes.
Thus, it is important to determine whether existing PIM measurement tools
can be used to define PIM use as more than an “ever-never” exposure when
investigating cognitive outcomes of such use. To address this gap in the literature,
this study uses existing PIM measurement tools to identify varying extents of
exposure to PIM use and to investigate whether such use is significantly
associated with one-year cognitive decline.

3.3.2 Methods
3.3.2.1 Population and Study Design
Data used in this study was obtained from participants at Alzheimer’s Disease
Centers (ADCs) throughout the United States from June 2005 to December 2019.
The US National Institute on Aging began the ADC program in 1984 in a
comprehensive effort to boost research on Alzheimer’s disease and related
disorders.106 As part of their participation in the ADC program, Centers
prospectively collect demographic, clinical, neuropsychological, and diagnostic
patient data and provide it to the National Alzheimer’s Coordinating Center (NACC)
in a standardized manner. NACC then deidentifies the data and makes it available
to researchers in the form of a Uniform Data Set (UDS).107 Due to its deidentified
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nature, use of data obtained from NACC was exempted from review by the
Institutional Review Board.
In this retrospective cohort study with a new-user design, we used data from
participants' second visit to establish baseline characteristics, and data from
participants' initial visit to determine user status at the second visit (new, prevalent,
or never user). Participants living in the community that had a second visit to an
ADC in or before October 2018 while aged at least 65 years were included to
ensure all participants had equal opportunity for follow-up. Participants were
excluded if they reported no medication use or if their cognitive status could not
worsen at their second visit (i.e. a maximum score on the cognitive scale described
below). Participants were considered lost to follow-up if there was no subsequent
visit to an ADC, or if a subsequent visit occurred but was outside a 6-25 month
period after the second visit, and were administratively censored at the end of the
data in December 2019.
3.3.2.2 Potentially Inappropriate Medication Identification
ADCs are required to ask participants to report all prescription medications taken
in the two weeks before each visit. While non-prescription medications need not
be reported, centers are permitted to include them in a participants’ medication list
if desired. Centers are permitted to list up to forty medications for each participant,
which are classified according to the Cerner MultumTM Lexicon Plus
nomenclature.173
For the purposes of this study, PIM users were identified based on
participants self-report of current medication use at their second visit to the ADC.
Included ADC participants were identified as PIM users at different levels based
on whether their medication use met the cutoff definition from any of the three PIM
assessment tools. These definitions included polypharmacy (defined as both ≥4
and ≥5 total medications) and medications present in existing explicit criteria (≥1,
≥2, and ≥3 PIMs as identified in Beers 2015 and STOPP v2). In addition, both
Beers and STOPP criteria include a sub-list of medications that are potentially
inappropriate for older adults with cognitive impairment or dementia based on
existing evidence suggesting that these medications may negatively impact
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cognition. Thus, we also defined PIM users as those who use ≥1 or ≥2 medications
included in such lists as "Cog-Beers" and "Cog-STOPP" medications. Cog-Beers
medications included all anticholinergic and antimuscarinic medications,
benzodiazepines, histamine-2 receptor antagonists, hypnotics, and antipsychotics.
Cog-STOPP medications included tricyclic antidepressants, all anticholinergic and
antimuscarinic medications, antipsychotics, and hypnotics.
Users were considered "new" if they reported any medication that met the
above definitions at the second visit, but not at the first visit. PIM users were
considered "prevalent" if they reported said medications at both the initial and
second visits. Participants who reported no such medications at either initial or
second visit were considered "never" users. Prevalent and past users were not
included in this analysis to avoid selection bias that might occur if long-term PIM
users are more likely to experience cognitive decline.174
At the time this study was conducted, Beers 2015 was the most recent
version of this tool available. Due to information on presence of insomnia and
arthritis type only being reported in the UDS since 2015, no medications
considered inappropriate only in the presence of these comorbidities were included
as PIMs for the purposes of this study.
3.3.2.3 Degree of Cognitive Decline
Using PIM use at the enrollment visit as the exposure, this study investigated the
effect each level of baseline PIM exposure had on the degree of participants’
cognitive decline after approximately one year (6-25 months). Cognition at the
second and next ADC visit was measured using the CDR® Staging Instrument
summated score (CDR-SOB).175 The primary outcome in this study, cognitive
decline, was defined as the difference in CDR-SOB between the second and next
ADC visit. If a participant’s cognition improved after the second visit (a negative
difference), the outcome was coded as a 0 (in other words, “no degree of cognitive
decline”) because such a finding is likely due to misclassification, differences in
diagnostic criteria, or within-patient variability.176
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3.3.2.4 Covariates
Participants’ demographic characteristics (including sex, age, years of education,
marital status, and race) at baseline were included as covariates in this study.
Additionally, clinical profiles were documented by recording the presence
(recent/active or remote/history) of the following conditions: atherosclerotic
cardiovascular disease, depression (within the last two years), diabetes,
hypertension, Parkinson’s disease, and seizures. The directed acyclic graph used
to select these covariates can be found in Figure 3.3.2. Additionally, any covariates
unable to be balanced using the inverse probability of treatment and censoring
weights were included in the final model.
Genetic predisposition to cognitive impairment is an important confounding
factor in any analysis investigating cognitive decline risk factors177, but only about
70% of ADC participants provide this information. Thus, while heredity was not
included as a covariate in primary analyses a supplemental analysis, stratified by
the presence of a first-degree family member with cognitive impairment was
conducted.
3.3.2.5 Statistical Analysis
Normality for all variables was assessed visually with Q-Q plots, and normally
distributed continuous variables were described using the mean and standard
deviation (SD), while the median and interquartile range (IQR) were used to
describe non-normally distributed variables. Chi-squared, Student’s t, and
Wilcoxon Mann-Whitney U tests178 were used to compare characteristics as
appropriate.
Each exposure was modeled in a negative binomial regression with inverse
probability of treatment and censoring weights (IPW) adjusted for covariates
described above in the primary and supplemental analyses. IPWs were
constructed to account for both PIM exposure definition and differential loss to
follow-up. Each model provided an estimate of the rate ratio (RR) for one-year
cognitive decline, with robust standard errors and 95% confidence intervals (CI),179
using the Dunnett-Hsu's adjustment for multiple comparisons (see Code Block
3.3.1). An offset was included as the natural log of follow-up time.
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In order to ensure that the IPWs were constructed correctly, we first
checked the average weight and pseudo-population size for each exposure
definition. Then, to check that conditional exchangeability held, we checked that
the differences that existed between PIM user groups in the unweighted data were
eliminated in the weighted data. Positivity was checked by verifying that at there
was at least one participant in each exposure group. Though consistency could
not be checked directly with the data, by carefully constructing exposure definitions
to match clinical usage patterns, we did our best to ensure that each exposure
definition corresponded to only one version of treatment.
All statistical analyses were conducted in SAS 9.4.109 This work was
supported by the National Institutes of Health (NIH)/National Institute on Aging
(NIA) Grant R01 AG054130. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National Institutes of
Health. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC
data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman,
MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI James
Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan
Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI
Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P30 AG06242101 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD,
PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas
Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI
Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI
Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50
AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD,
PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow,
MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry
Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50
AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30
AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD),
P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay
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Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI
Stephen Strittmatter, MD, PhD).

3.3.3 Results
3.3.3.1 Baseline Participant Characteristics
Of 27,657 ADC participants, 14,109 were ultimately included in the study (see
Figure 3.3.1). The most common reason for study exclusion was age < 65 years
at the baseline visit, and the most common reason for loss to follow-up was lack
of a subsequent visit.
Among all included participants, the median time to next visit was
approximately 12.5 months. As can be seen in Table 3.3.1, included participants
were an average of 77 years old at their baseline visit, slightly more than half of
the participants were female, and a large majority were of white race. While the
median CDR-SOB was only 0.5, approximately 50% of participants had impaired
cognition at baseline based on clinical diagnoses.
After applying inverse probability weights for treatment and censoring, participants
who were new users of any Cog-Beers medication were not different from those
who never used Cog-Beers medications, except that Cog-Beers users reported
more medications than nonusers (see Table 3.3.1). These findings persisted for
all exposure definitions,

and

both weighted and unweighted baseline

characteristics can be found in Supplementary Table 3.3.2 through Supplementary
Table 3.3.5.
.
3.3.3.2 Exposure Definitions
There was significant participant overlap amongst the various PIM exposure
definitions (see Figure 3.3.3). Nearly all (99.5%) Cog-STOPP users were also CogBeers users, but only 46.5% of Cog-Beers users were also Cog-STOPP users.
Only 27.5% of Beers users were also Cog-Beers users. Similarly, only 19.4% of
STOPP users were also Cog-STOPP users. Over half of participants with four or
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more medications were Beers and/or STOPP users, while 23.8 and 10.6% of those
participants were also Cog-Beers and Cog-STOPP users respectively.
Approximately three-quarters of Cog-Beers, Cog-STOPP, Beers, and STOPP
users also used at least four medications concurrently.
Regardless of PIM exposure definition the most common medication class
used was nutritional products, ranging from 19.3% of medications reported in new
Beers criteria medication users to 12.3% of medications reported for participants
with polypharmacy (see Table 3.3.2). Analgesics were the second most common
medication class followed by antihyperlipidemics. Complete data on medication
class prevalence for exposed and unexposed participants will be available upon
request.
The

most

commonly

reported

Cog-Beers

medication

class

was

antidepressants, compared to benzodiazepines for Cog-STOPP. Antidepressants,
bladder antimuscarinics, benzodiazepines and antihistamines were the most
prevalent

Cog-Beers

and

Cog-STOPP

medications

reported.

Whereas

antidepressants were 33.0% of reported Cog-Beers medications, they only
represented 10.0% of Cog-STOPP medications. Similarly, 32.0% of Cog-STOPP
medications were benzodiazepines, compared to only 10.7% of Cog-Beers
medications.
3.3.3.3 Checking Model Assumptions
The average weight for each exposure definition was approximately 0.95, making
each pseudo-population approximately the same size as the original population
without missing values (see Supplementary Table 3.3.1).
The values of each covariate between PIM use groups were compared from
the unweighted conditions to weighted conditions, confirming that standardized
mean differences between groups were lower after weighting (see Table 3.3.1 and
Supplementary Table 3.3.2 through Supplementary Table 3.3.5). The exception to
this finding is the covariate for number of medications participants reported using
at baseline. Because this covariate is closely related to the exposure, it was unable
to be balanced using the IPW. Thus, for all models except the Polypharmacy PIM
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use definition, an indicator for polypharmacy was also included as a covariate in
the model, as described in Section 3.3.2.4.
After running the negative binomial regression model, we determined that
the mean of the outcome was significantly lower than the standard deviation,
suggesting that the model is the appropriate choice.
3.3.3.4 Rate of Cognitive Decline
After adjusting for known confounders and applying inverse probability weights for
treatment and censoring, the mean rate of cognitive decline was significantly lower
for PIM nonusers who were cognitively unimpaired at baseline compared to
nonusers who were cognitively impaired at baseline (see Table 3.3.3). The highest
rate of nonuser cognitive decline was for impaired Cog-STOPP nonusers (mean
[95% CI] increase of 2.1 [1.7-2.6] CDR-SOB per person-year). Unimpaired
nonusers of STOPP PIMs had the lowest rate of cognitive decline amongst the
unimpaired and unexposed (0.16 [0.07-0.36] per person-year).
Amongst participants who were cognitively impaired at baseline, new use
of one Cog-Beers or Cog-STOPP medication was associated with a significant
increase in the rate of cognitive decline per person-year compared to never having
used a medication in either PIM criteria (RR [95% CI] 1.20 [1.04-1.39] and 1.26
[1.07-1.47], respectively; see Figure 3.3.4). In most exposure definitions, use of
more medications in the criteria was associated with a larger point estimate for rate
of person-year cognitive decline with the exception of use of ≥2 medications in
Cog-STOPP and ≥3 medications in Beers criteria.
Amongst participants who cognitively normal at baseline, no definition of
PIM use was associated with a significantly different rate of cognitive decline per
person-year.
A sensitivity analysis excluding participants whose CDR-SOB score
decreased at the second visit (i.e., back-transitioners) did not reveal significantly
different results (see Supplementary Figure 3.3.1). A sensitivity analysis excluding
participants for whom no family history was known revealed the same trends as
the main analysis, with significant effects on rate of cognitive decline only for new
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users of Cog-Beers and/or Cog-STOPP PIMs with baseline cognitive impairment
and family history of cognitive impairment (see Supplementary Table 3.3.6).

3.3.4 Discussion
It is currently unknown whether any of the widely used explicit criteria for identifying
potentially inappropriate medication use in older adults can be used to direct
clinical decisions regarding the effect of these potentially inappropriate
medications on cognitive outcomes. In this study, we used varying cutoffs for PIM
use definitions based on widely used medication assessment tools, including
Beers and STOPP criteria, and polypharmacy. We investigated whether
participants in a large, national cohort identified as new PIM users had a higher
rate of cognitive decline per person-year compared to participants who were not
PIM users according to any of the cutoffs.
We found that new users of one PIM in the Cog-Beers or Cog-STOPP
criteria declined at 1.20 or 1.26 times the rate per person-year compared to
nonusers. These criteria are more specific to cognitive outcomes than the
complete Beers and STOPP criteria, and the findings in this study provide further
evidence that use of medications in these sub-lists by patients with cognitive
impairment may be detrimental to preserving cognition. However, there were no
significant effects of Cog-Beers or Cog-STOPP PIM use on cognitive decline
amongst participants who were cognitively normal at baseline. This finding could
be attributed to the fact that rates of cognitive decline in participants never exposed
to PIMs were so low that small effects could not be identified in such small sample
sizes. Repeating a similar study in a larger population over longer periods of time
may provide a more meaningful result.
Interestingly, while over 90% of participants identified as Cog-STOPP PIM
users were also Cog-Beers PIM users, only approximately 45% of Cog-Beers PIM
users were also Cog-STOPP PIM users. This is likely because Cog-Beers includes
such commonly used medications as benzodiazepines and histamine-2 receptor
antagonists, while Cog-STOPP does not. Despite this difference in the definition
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of PIM use, however, the effect sizes for PIM use on cognitive decline were similar.
This suggests that the effect may be driven by the medications in common
between the two criteria: anticholinergics, antipsychotics, and hypnotics.
However, despite the fact use of one medication in the Cog-Beers and CogSTOPP criteria was associated with an increased rate of per-person year cognitive
decline after approximately one year, the confidence intervals of each estimate
indicate that there is no statistically significant difference in the rate of cognitive
decline between new PIM users and nonusers amongst the various PIM use
definitions. These results suggest that none of the widely used explicit criteria
perform exceptionally different when attempting to identify PIM use to protect
cognitive function. While most point estimates indicated an increased rate of
cognitive decline with increased use of PIMs, sample sizes were too small and
variability too high to confidently infer an association.
Previous studies have concluded that the odds of being diagnosed with
dementia over a six-year period increased by a factor of 2.3 for every point
increase in the CDR-SOB.180 We did not see such a drastic increase in the CDRSOB, which may be because of the significantly shorter follow-up time in this study
(median time to next visit ~13 months). Furthermore, while a clinical diagnosis of
dementia was not used as the outcome in this study due to the short follow-up, the
CDR-SOB outcome correlated well with a clinician’s assessment of meaningful
decline in memory, non-memory cognitive abilities, behavior, ability to manage
his/her affairs, or there are motor/movement changes (see Supplementary Table
3.3.7).
This study undertook rigorous statistical adjustment methods to account for
bias introduced in many observational investigations of cognitive decline. Namely,
because cognitive decline is a strong risk factor for loss to follow-up, this study
weighted participants according to their probability of being lost to follow-up and
their probability of being classified as PIM users in the various definition schema.
In so doing, selection and indication bias have been largely eliminated.
While the NACC UDS provides longitudinal information on many important
health outcomes and behaviors for older adults, there are shortcomings to using
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survey data when investigating questions of causality. While we attempted to
minimize the effect of extended unobserved time periods between participants'
visits to ADCs by restricting only to participants who had follow-up visits within 625 months, the data remains interval-censored. The assumption that participants'
medication reports at the second visit represent their actual use until the follow-up
visit is a strong assumption that may introduce confounding. However,
misclassifying nonusers as new users or vice-versa would bias effect estimates
toward the null. This misclassification may be one reason why only PIM use
defined by Cog-Beers and Cog-STOPP criteria showed statistically significant
effect sizes.
Overall, these results add evidence to using the sub-lists within Beers or
STOPP criteria to identify targeted PIMs in patients with cognitive impairment,
particularly those with a family history of cognitive decline. However, there were
no statistically significant differences in rate of cognitive decline amongst the
various cutoffs of various definitions of PIM use. Accordingly, this study does not
support the use of one PIM measurement tool over another for clinicians interested
in managing medication regimens. Future studies should continue this work, taking
into account the potential cumulative dosage effect and considering a longer
follow-up time.
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3.3.5 Tables and Figures
Table 3.3.1. Baseline Characteristics of Cog-Beers Use in NACC Population
Unweighted
Total
n = 9108

Unweighted
New
Never
Cog-Beers
Cog-Beers
n = 891
n = 8217

|SMD|

New
Cog-Beers
n = 875

Weighted
Never
Cog-Beers
n = 7785

|SMD|
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Demographics
Age, years, mean (SD)
76.43 (7.03)
76.9 (7.25)
76.38 (7)
0.077
77.19 (7.27)
76.59 (6.82)
0.084
Female
5010 (55.01)
509 (57.13)
4501 (54.78) 0.079
478 (54.63)
4329 (55.61) 0.024
White race
7585 (83.28)
710 (79.69)
6875 (83.67) 0.083
685 (78.29)
6408 (82.31) 0.104
Years education, mean (SD)
15.28 (3.39)
14.93 (3.66) 15.31 (3.36)
0.123
14.92 (3.72)
15.09 (3.4)
0.046
Days to next visit, median (IQR) 379 (357-430)
384 (358-437) 378 (357-429) 0.043
384 (357-433) 378 (357-429) 0.028
Clinical characteristics
ASCVD
1227 (13.47)
151 (16.95)
1076 (13.09) 0.117
108 (12.34)
1180 (15.16) 0.068
Depression
2232 (24.51)
300 (33.67)
1932 (23.51) 0.224
214 (24.46)
2257 (28.99) 0.073
Diabetes
1252 (13.75)
166 (18.63)
1086 (13.22) 0.147
147 (16.8)
1120 (14.39) 0.080
Hypertension
5365 (58.9)
575 (64.53)
4790 (58.29) 0.127
539 (61.6)
4691 (60.26) 0.028
Impaired cognition*
4866 (53.43)
544 (61.05)
4322 (52.6)
0.161
527 (60.23)
4446 (57.11) 0.070
Parkinson’s disease
130 (1.43)
20 (2.24)
110 (1.34)
0.067
15 (1.71)
153 (1.97)
0.017
Seizures
190 (2.09)
27 (3.03)
163 (1.98)
0.073
19 (2.17)
184 (2.36)
0.008
Medications, median (IQR)
6 (3-8)
8 (5-10)
5 (3-8)
0.592
7 (10-5)
6 (3-8)
0.517
CDR-SOB, median (IQR)
0.5 (0-3.5)
1 (0-5)
0.5 (0-3)
0.245
1 (0-5)
0.5 (0-4)
0.132
Cog-Beers: medications affecting cognition in Beers Criteria; SMD: standardized mean difference; ASCVD: atherosclerotic
cardiovascular disease; CDR-SOB: CDR Staging Instrument sum of boxes
* Based on clinical assessment

Table 3.3.2. Distribution of PIM Use by Medication Class
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nutritional products
analgesics
antihyperlipidemic agents
antidepressants
alternative medicines
cholinesterase inhibitors
hormones/hormone modifiers
respiratory agents
diuretics
beta-adrenergic blocking agents
topical agents
ACE inhibitors

Cog-Beers
15.25%
9.14%
6.53%
5.80%
4.62%
4.46%
4.40%
3.16%
3.05%
2.98%
2.96%
2.89%

Cog-STOPP
14.29%
8.58%
6.37%
4.40%
4.34%
4.26%
4.55%
3.32%
3.06%
2.69%
2.62%
2.65%

Beers
19.34%
11.72%
7.50%
3.22%
5.77%
4.55%
4.34%
2.58%
3.13%
3.49%
2.36%
3.31%

STOPP
18.90%
11.32%
6.97%
3.16%
5.75%
3.77%
4.28%
3.74%
3.31%
3.09%
2.43%
2.77%

Polypharmacy
12.25%
8.23%
10.50%
4.90%
2.79%
7.66%
5.82%
1.93%
3.90%
4.59%
2.29%
4.85%

Table 3.3.3. Adjusted Mean Cognitive Decline Per Unexposed Person-Year

Cog-Beers
Cog-STOPP
Beers
STOPP
Polypharmacy

Mean
2.12
2.11
1.94
1.84
1.33

Impaired
95% CI
1.72-2.61
1.73-2.58
1.40-2.69
1.26-2.70
0.77-2.32

Mean
0.26
0.27
0.20
0.16
0.42

Unimpaired
95% CI
0.11-0.59
0.12-0.59
0.09-0.44
0.07-0.36
0.15-1.22

Figure 3.3.1. Participant Selection
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Figure 3.3.2. Directed Acyclic Graph for PIM Use on Cognitive Decline
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Figure 3.3.3. Overlap in PIM Exposure Definitions

85

Figure 3.3.4. Cognitive Decline by PIM Exposure Definition
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3.3.6 Supplementary Data
Supplementary Table 3.3.1. Distribution of Inverse Probability Weights
Exposure
Cog-Beers
Cog-STOPP
Beers
STOPP
Polypharmacy

Weight, mean
0.955
0.955
0.948
0.950
0.919

n, weighted
8659
9171
4538
5243
3435

n, unweighted
9108
9649
4857
5549
3754
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Supplementary Table 3.3.2. Baseline Characteristics by Cog-STOPP Use
Unweighted
Total
n = 9649

Unweighted
New
Never CogCog-STOPP
STOPP
|SMD|
n = 767
n = 8882
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Demographics
Age, years, mean (SD)
76.55 (7.06)
76.94 (7.21)
76.52 (7.04) 0.054
Female
5290 (54.82)
442 (57.63)
4848 (54.58) 0.087
White race
8059 (83.52)
620 (80.83)
7439 (83.75) 0.068
Years education, mean (SD) 15.27 (3.4)
14.99 (3.6)
15.29 (3.38) 0.106
Days to next visit, median
379 (357-430)
385 (358-441) 378 (357-429) 0.041
(IQR)
Clinical characteristics
ASCVD
1435 (14.87)
118 (15.38)
1317 (14.83) 0.029
Depression
2383 (24.7)
277 (36.11)
2106 (23.71) 0.272
Diabetes
1345 (13.94)
140 (18.25)
1205 (13.57) 0.129
Hypertension
5725 (59.33)
503 (65.58)
5222 (58.79) 0.139
Impaired cognition*
5143 (53.3)
483 (62.97)
4660 (52.47) 0.213
Parkinson’s disease
138 (1.43)
18 (2.35)
120 (1.35)
0.073
Seizures
203 (2.1)
25 (3.26)
178 (2)
0.085
Medications, median (IQR)
6 (4-8)
8 (5-11)
6 (3-8)
0.592
CDR-SOB, median (IQR)
0.5 (0-3.5)
1 (0-5)
0.5 (0-3)
0.304
Cog-STOPP: medications affecting cognition in STOPP Criteria; SMD: standardized mean
cardiovascular disease; CDR-SOB: CDR Staging Instrument sum of boxes
* Based on clinical assessment

Weighted
New
Never
Cog-STOPP Cog-STOPP
n = 752
n = 8418
77.42 (7.17)
405 (53.86)
600 (79.79)
15.02 (3.59)

76.66 (6.88)
4707 (55.92)
6931 (82.34)
15.06 (3.45)

|SMD|
0.109
0.042
0.065
0.014

384 (358-434) 378 (357-429) 0.03
108 (14.36)
1291 (15.34) 0.028
182 (24.2)
2456 (29.18) 0.113
127 (16.89)
1210 (14.37) 0.07
472 (62.77)
5081 (60.36) 0.049
463 (61.57)
4800 (57.02) 0.091
13 (1.73)
173 (2.06)
0.029
18 (2.39)
194 (2.3)
0.001
8 (5-10)
6 (4-8)
0.527
1 (0-5)
0.5 (0-4.5)
0.12
difference; ASCVD: atherosclerotic

Supplementary Table 3.3.3. Baseline Characteristics by Beers Use
Unweighted
Total
n = 4857

Unweighted
New Beers
Never Beers
n = 1666
n = 3191

|SMD|

New Beers
n = 1610

Weighted
Never Beers
|SMD|
n = 2973
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Demographics
Age, years, mean (SD)
76.58 (7.21)
76.61 (7.12)
76.56 (7.26)
0.026
76.84 (7.06) 76.72 (7)
Female
2796 (57.57)
909 (54.56)
1887 (59.14)
0.083
913 (56.71)
1641 (55.2)
White race
4012 (82.6)
1352 (81.15)
2660 (83.36)
0.066
1285 (79.81) 2421 (81.43)
Years education, mean (SD)
15.24 (3.38)
15.06 (3.5)
15.34 (3.31)
0.088
14.92 (3.54) 15.14 (3.35)
Days to next visit, median (IQR) 378 (357-430)
378 (357-430)
378 (357-430)
0.003
378 (357-430) 378 (357-430)
Clinical characteristics
ASCVD
617 (12.7)
246 (14.77)
371 (11.63)
0.105
218 (13.54)
444 (14.93)
Depression
1140 (23.47)
427 (25.63)
713 (22.34)
0.082
402 (24.97)
851 (28.62)
Diabetes
529 (10.89)
236 (14.17)
293 (9.18)
0.164
211 (13.11)
389 (13.08)
Hypertension
2674 (55.05)
1021 (61.28)
1653 (51.8)
0.191
936 (58.14)
1766 (59.4)
Impaired cognition*
2565 (52.81)
913 (54.8)
1652 (51.77)
0.072
923 (57.33)
1663 (55.94)
Parkinson’s disease
79 (1.63)
30 (1.8)
49 (1.54)
0.025
33 (2.05)
57 (1.92)
Seizures
102 (2.1)
34 (2.04)
68 (2.13)
0.006
35 (2.17)
71 (2.39)
Medications, median (IQR)
5 (3-7)
6 (4-9)
4 (2-6)
0.773
6 (4-8)
4 (2-6)
CDR-SOB, median (IQR)
0.5 (0-3.5)
0.5 (0-4)
0.5 (0-3.5)
0.042
0.5 (0-4.5)
0.5 (0-4)
Beers: medications in Beers Criteria; SMD: standardized mean difference; ASCVD: atherosclerotic cardiovascular disease; CDR-SOB:
CDR Staging Instrument sum of boxes
* Based on clinical assessment

0.017
0.031
0.04
0.062
0.006
0.04
0.083
0.001
0.026
0.028
0.009
0.016
0.733
0.051

Supplementary Table 3.3.4. Baseline Characteristics by STOPP Use
Unweighted
Total
n = 5549

Unweighted
New
Never
STOPP
STOPP
n = 1762
n = 3787

|SMD|

Weighted
New
Never
STOPP
STOPP
n = 1698
n = 3545

|SMD|
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Demographics
Age, years, mean (SD)
76.5 (7.2)
76.77 (7.14)
76.37 (7.22)
0.069
76.89 (7.07)
76.7 (7)
0.027
Female
3253 (58.62)
972 (55.16)
2281 (60.23)
0.111
977 (57.54)
1995 (56.28)
0.026
White race
4632 (83.47)
1445 (82.01)
3187 (84.16)
0.054
1384 (81.51)
2879 (81.21)
0.008
Years education, mean (SD) 15.23 (3.38)
15.11 (3.46)
15.29 (3.34)
0.074
15.01 (3.44)
15.04 (3.44)
0.009
Days to next visit, median
378 (357-430) 380 (357-432) 378 (357-430) 0.014
379 (357-430) 378 (357-432) 0.017
(IQR)
Clinical characteristics
ASCVD
701 (12.63)
261 (14.81)
440 (11.62)
0.117
228 (13.43)
518 (14.61)
0.034
Depression
1349 (24.31)
474 (26.9)
875 (23.11)
0.09
439 (25.85)
1030 (29.06)
0.072
Diabetes
582 (10.49)
248 (14.07)
334 (8.82)
0.172
209 (12.31)
468 (13.2)
0.027
Hypertension
2872 (51.76)
1106 (62.77)
1766 (46.63)
0.327
951 (56.01)
2079 (58.65)
0.054
Impaired cognition*
2901 (52.28)
976 (55.39)
1925 (50.83)
0.121
969 (57.07)
1980 (55.85)
0.025
Parkinson’s disease
89 (1.6)
29 (1.65)
60 (1.58)
0.009
32 (1.88)
70 (1.97)
0.007
Seizures
116 (2.09)
39 (2.21)
77 (2.03)
0.016
38 (2.24)
82 (2.31)
0.006
Medications, median (IQR) 5 (3-7)
6 (5-9)
4 (2-6)
0.807
6 (5-9)
4 (3-6)
0.748
CDR-SOB, median (IQR)
0.5 (0-3)
0.5 (0-3.5)
0.5 (0-3)
0.049
0.5 (0-4)
0.5 (0-4)
0.016
STOPP: medications in STOPP v2 Criteria; SMD: standardized mean difference; ASCVD: atherosclerotic cardiovascular disease;
CDR-SOB: CDR Staging Instrument sum of boxes
* Based on clinical assessment

Supplementary Table 3.3.5. Baseline Characteristics by Polypharmacy Use
Unweighted
Total

Unweighted
New
Never
Polypharmacy Polypharmacy |SMD|
n = 1708
n = 2046

Weighted
New
Never
Polypharmacy Polypharmacy |SMD|
n = 1706
n = 1729
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n = 3754
Demographics
Age, years, mean (SD)
76.42 (7.27)
76.43 (7.17)
76.41 (7.36)
0.014
76.53 (7.19)
76.79 (6.95)
0.036
Female
2163 (57.62)
976 (57.14)
1187 (58.02)
0.006
985 (57.74)
1002 (57.95)
0.004
White race
3133 (83.46)
1396 (81.73)
1737 (84.9)
0.068
1386 (81.24)
1391 (80.45)
0.022
Years education, mean (SD)
15.18 (3.35)
15.09 (3.43)
15.26 (3.28)
0.062
14.96 (3.48)
15.06 (3.14)
0.030
Days to next visit, median (IQR) 379 (359-433)
379 (360-437) 379 (358-430) 0.052
379 (359-436) 380 (358-433) 0.036
Clinical characteristics
ASCVD
384 (10.23)
230 (13.47)
154 (7.53)
0.192
202 (11.84)
226 (13.07)
0.039
Depression
736 (19.61)
401 (23.48)
335 (16.37)
0.181
383 (22.45)
430 (24.87)
0.057
Diabetes
263 (7.01)
173 (10.13)
90 (4.4)
0.222
151 (8.85)
211 (12.2)
0.110
Hypertension
1653 (44.03)
881 (51.58)
772 (37.73)
0.282
789 (46.25)
962 (55.64)
0.189
Impaired cognition*
1793 (47.76)
889 (52.05)
904 (44.18)
0.17
912 (53.46)
888 (51.36)
0.042
Parkinson’s disease
40 (1.07)
22 (1.29)
18 (0.88)
0.044
23 (1.35)
30 (1.74)
0.032
Seizures
62 (1.65)
36 (2.11)
26 (1.27)
0.064
34 (1.99)
33 (1.91)
0.008
Medications, median (IQR)
3 (2-5)
5 (4-7)
2 (1-3)
2.168
5 (4-7)
2 (2-3)
2.158
CDR-SOB, median (IQR)
0 (0-2.5)
0.5 (0-3)
0 (0-1.5)
0.123
0.5 (0-3.5)
0.5 (0-3)
0.019
SMD: standardized mean difference; ASCVD: atherosclerotic cardiovascular disease; CDR-SOB: CDR Staging Instrument sum of boxes
* Based on clinical assessment

Supplementary Table 3.3.6. PIM Use on Cognitive Decline by Family History

92

Impaired Baseline Cognition
Normal Baseline Cognition
FH
No FH
FH
No FH
RR
95% CI
RR
95% CI
RR
95% CI
RR
95% CI
Cog-Beers 2015
1
1.3453 1.1277 1.6049 0.9842 0.7759 1.2484
1.106
0.3783 3.2335 0.7326 0.2712
≥2 1.5131 0.7811 2.931
1.2155 0.4957 2.9805
0.8165 0.2048 3.2558 1.6148 0.4598
Cog-STOPP v2
1
1.4381 1.1867 1.7428 1.0148 0.776
1.3271
1.2354 0.3723 4.0989 1.0046 0.2896
≥2 1.1482 0.5691 2.3165 0.9831 0.5007 1.9302
0.8513 0.2412 3.0044 1.55
0.4994
Beers 2015
1
1.0484 0.8366 1.3138 1.2106 0.8637 1.6968
0.9511 0.4506 2.0077 0.8352 0.4345
2
1.249
0.8985 1.7362 1.2757 0.7341 2.2169
0.6869 0.2179 2.1655 0.863
0.3779
≥3 1.4462 0.7603 2.751
0.982
0.5901 1.6343
1.2764 0.334
4.8779 0.8532 0.08375
STOPP v2
1
1.0241 0.805
1.3027 1.1499 0.7997 1.6534
1.1684 0.5874 2.3241 0.6002 0.2057
2
1.126
0.8621 1.4707 0.9769 0.6371 1.4979
1.6542 0.51
5.3655 0.9844 0.4431
≥3 1.2479 0.7701 2.0221 0.7839 0.3398 1.8085
0.2997 0.05905 1.5215 0.8395 0.2337
Total medications
4
1.0541 0.7599 1.462
1.1614 0.7182 1.8782
0.7147 0.2767 1.8458 0.8832 0.3249
≥5 1.2487 0.9892 1.5762 0.9682 0.6819 1.3747
0.6251 0.2677 1.4598 0.8771 0.4378
FH: family history of cognitive impairment; CI: confidence interval; RR: rate ratio

1.9792
5.6709
3.4854
4.8109
1.6056
1.9706
8.6924
1.7511
2.1871
3.016
2.4009
1.7569

Supplementary Table 3.3.7. Validity of CDR-SOB Outcome by PIM Use
Cog-Beers
PIM Users
Possible Gold Standards
Ss
Sp
PPV NPV

Ss

Cog-Beers
PIM Nonusers
Sp
PPV NPV

Subject reports a decline in memory

0.55

0.75

0.77

0.54

0.55

0.78

0.72

0.62

Co-participant reports a decline in memory

0.63

0.50

0.55

0.58

0.62

0.88

0.86

0.65

0.91

0.91

0.65

Clinician believes there is a meaningful decline in
memory, non-memory cognitive abilities, behavior, ability
0.63 0.91 0.93 0.55
0.62
to manage his/her affairs, or there are motor/movement
changes
Ss: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value
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Supplementary Figure 3.3.1. Sensitivity Analysis Excluding Back-Transitions
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3.3.7 Code Blocks
Code Block 3.3.1. Negative Binomial Regression for Degree of Cognitive Decline
proc sort data=final; by impair; format _all_; run;
title "Cog-Beers Count: New vs Never";
proc genmod data = final;
by impair;
class cnsb_new(ref="0") sex(ref="0") dep2yrs(ref="0") cardiodz(ref="0")
diabetes(ref="0") pd(ref="0") seizures(ref="0") hyperten(ref="0") naccid;
model cdrchange_trunc = cnsb_new sex naccage educ dep2yrs cardiodz diabetes pd
seizures hyperten cdrsum2 poly4 / type3 link=log dist=negbin offset=ln_fuyrs; *log link
assumed and not necessary;
weight swcnsb;
repeated subject = naccid;
lsmeans cnsb_new / ilink diff exp cl pdiff=control('0') adjust=dunnett; /*
estimates rate ratios */
run; quit;title;
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3.4

Cumulative dose effects of potentially inappropriate medication use
on dementia diagnosis in an older adult Medicare population

3.4.1 Introduction
Potentially inappropriate medication (PIM) use in older adults is highly prevalent
throughout the world.40 There are many ways researchers and clinicians identify
and define PIMs, ranging from nuanced implicit criteria that require a great deal of
clinical judgment but are generally highly accurate, to broad explicit criteria
containing lists of many medication classes that may not be applicable to all
patients, to targeted criteria of one or a few medication classes known to be
detrimental for certain health outcomes. Because dementia is the fifth leading
cause of death for Americans over 65 years of age, there is no effective treatment
or cure, and many with dementia also have other comorbidities,181 it is important
that medication therapy in these individuals not contribute to negative cognitive
outcomes. However, the multimorbid state of many older adults with dementia can
lead to polypharmacy and increase the chances that any one medication may be
potentially inappropriate.
In fact, a recent systematic review found that 14-74% of older adults with
dementia

used

PIMs,

driven

by

benzodiazepines,

hypnotics,

and

anticholinergics.40 Given that there is evidence linking each of these individual
medication classes to a variety of negative cognitive effects,65,122 it is important
that their use is effectively and accurately measured so that interventions can be
designed to reduce consumption of these potentially inappropriate medications.
While there have been numerous tools developed to aid in PIM use measurement
over the last few decades, there is inconsistency in their application clinically and
in research,38,40 as well as in their association to health outcomes, specifically
cognitive decline. One of the most widely-used medication appropriateness
assessment tool in the United States is the Beers Criteria. Initially developed in
1991, and currently in its sixth update, the Beers Criteria explicitly list medications
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that should be avoided in all older adults. Beginning in 2003, the Beers Criteria
included a sub-list of medications that should be considered potentially
inappropriate in older adults with dementia or cognitive impairment (Cog-Beers).
This

list

includes

benzodiazepines,

medications

with

non-benzodiazepine

strong

anticholinergic

hypnotics,

histamine-2

properties,
receptor

antagonists, and antipsychotics.115 Previous studies have defined PIM use by use
of any medication in this sub-list,128,182 and found that nearly one-quarter of older
adults with dementia used these potentially inappropriate medications, and we
have previously shown that using any medication in the Cog-Beers list may be
associated with and increased rate of cognitive decline over approximately one
year (see previous chapter).
However, no studies have investigated whether there is a dose-response
relationship in the association between Cog-Beers PIM use and cognitive decline.
While estimates of "ever-never" PIM use can be helpful in research, most
relationships yet to be elucidated are more nuanced in nature. The practice of
simplifying a complex exposure into inflexible dichotomous or ordinal variables
certainly has its flaws, but continues to be employed in medical research due to
the taxing computational and statistical tools required to analyze a more nuanced
exposure.183 Outside of the statistical power lost, a primary concern when defining
PIM use as a single exposure is that mounting evidence indicates the risks
anticholinergics,57,123 proton pump inhibitors184, and sedatives185 to cognition may
be dose-related,123 While it is not reasonable to expect that all future studies use
complex statistical techniques required to model such a nuanced exposure, it is
important to determine whether taking into account a dose-related effect when
using explicit criteria to define PIM use even matters.
Since 2006, Americans eligible for Medicare have had access to a
prescription drug benefit, which in addition to providing critical access to life-saving
therapies for a population in dire need, also paved the way for researchers to begin
to analyze prescription medication use trends in a large portion of the American
population. The Centers for Medicare and Medicaid Services (CMS) makes
deidentified administrative prescription claims processed through this program
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(Medicare Part D) available to researchers. In this study, we use these data to
investigate the effect of Cog-Beers PIM use on time to diagnosis of ADRD in a
population of adults 65 years old and above from 2012-2016.

3.4.2 Methods
3.4.2.1 Study Population and Data Source
This study utilized a random 5% sample of Medicare Part D (MPD) administrative
claims data for beneficiaries who were ≥ 65 years old at any point from 2012-2016,
had fee-for-service Medicare Parts A and B and were not dually eligible for
Medicaid for at least some point in that same time period. In addition to MPD
claims, this study also had access to enrollment files containing basic demographic
information, and a summary file detailing information on chronic and other
potentially disabling conditions.
Beneficiaries entered the study the day after their first six months of
continuous MPD eligibility (index date). Continuous enrollment was defined as
enrollment with no more than a one-month gap. In cases where gaps exceeded
one month, the end of continuous enrollment was the last day of the month prior
to the gap. Adults aged < 65 years, those with a diagnosis of Alzheimer's Disease
or related Dementias (ADRD), and those with any PIM use before the index date
were excluded. Beneficiaries exited the study at the first of: end of continuous
enrollment in MPD, diagnosis of ADRD, death, or the end of the data (12/31/2016).
3.4.2.2 Exposure
Medication use was derived from Medicare Part D (MPD) administrative claims
data. The data included the NDC, service date, quantity, and days supply for each
medication dispensed by a pharmacy that billed the patient's MPD plan.
Medications identified in the 2012 and 2015 Beers criteria as potentially
inappropriate for adults aged ≥ 65 years with Alzheimer's dementia and related
disorders (including anticholinergics, benzodiazepines, histamine-2 receptor
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antagonists, nonbenzodiazepine hypnotics, and antipsychotics) were considered
PIMs for the purposes of this study.
Cumulative PIM exposure was defined by first calculating the total dose
dispensed for each PIM identified in a prescription claim (strength x quantity).
Then, this total dose per prescription was converted to a standardized dose by
dividing the total dose per prescription claim by the minimum effective daily dose
for the most common indication according to the Geriatric Handbook in
Lexicomp186 (see Supplementary Table 3.4.1).
For each 28-day exposure period, the cumulative standardized doses
(CSDs) of PIMs were calculated as the summation of all standardized PIM doses
in prescription claims dispensed during that period. 28-day exposure periods were
chosen because previous studies have shown that this period is sufficient to
simulate a model with infinitely small intervals.187 Due to dose data having an
extremely right-skewed distribution, the top 1% of CSDs were truncated.
3.4.2.3 Outcome(s)
Clinical cognitive impairment was defined as a medical claim including a
Alzheimer's dementia and related disorders (ADRD) diagnosis. ADRD diagnoses
were defined as the presence of validated diagnosis codes at any position on an
inpatient, skilled nursing facility, home health agency, hospital outpatient, or
ambulatory claim. While using any position of the diagnosis code to identify ADRD
does increase sensitivity at the expense of specificity, the only data available to us
was this flag.
Previous studies have suggested that at least three years of continuous
eligibility are required to sufficiently identify Alzheimer's dementia and related
disorders in Medicare claims. The reason we do not need a 3-year run-in period is
because this has already been calculated by the Chronic Conditions Warehouse
and provided to us as a flag when at least 1 inpatient, SNF, HHA, HOP or carrier
claim with the included diagnosis codes was present in any of the 3 years prior to
inclusion in our study.
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3.4.2.4 Covariates
Based on published evidence, we created a directed-acyclic graph (DAG) to model
the relationship between factors involved with the exposure and outcome.
Covariates were included in the model based on their ability to control for
confounding identified by the DAG and their availability in the data (see Figure
3.4.1). Available and included covariates were as follows: age, sex, anxiety
disorder, depression, schizophrenia, bipolar disorder. Parkinson's disease could
not be included in the model because of its unavailability in the data.
3.4.2.5 Statistical Analysis
Data was converting into a counting process using the SAS macro program
%CPDATA,188 after the SAS procedure PROC PHREG was used to perform a Cox
proportional hazards regression to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) (see Code Block 3.4.1). Survival curves were
constructed for never exposed beneficiaries, as well as those with (0,50], (50,100],
(100,200], and (200,400] CSDs of Cog-Beers PIMs based on the distribution of
CSDs seen in the data.
Data was structured to include one row per person-time interval, with
columns to indicate the current exposure status (Cog-Beers PIM doses in the
current interval), cumulative exposure status (sum of standardized Cog-Beers PIM
doses over all earlier intervals in which a PIM prescription was current = CSDs),
covariate (i.e. age and comorbidity) status at the beginning of the interval, and
outcome status at the end of the interval.
To determine whether Cog-Beers PIM use was associated with the hazard
for ADRD, we used Cox proportional hazards regressions as in a previous study
investigating cumulative dose effects.187 In the first model, we included only an
indicator for ever-never use along with potential confounders, as specified above.
In the second model, we also included a linear term for cumulative exposure to
jointly control for time-invariant allocation bias (indication bias). Indication bias
occurs when the risk for the outcome is related to the exposure's indication, but
not the exposure itself. In this case, confounding by indication may be present
because ADRD is related to common PIM indications, which will cloud any
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association with PIMs themselves. Mathematically, this modeling is valid if one
considers the generalized linear model with terms for ADRD diagnosis (y),
cumulative exposure (x), an indicator for ever-never PIM use (z), and the link
function (g) (see Equation 3.1). As such, we can interpret the ever-exposure
parameter as the difference between ADRD risk at the start of PIM exposure
(⍺+𝛽𝛽0) and the ADRD risk in person-time intervals that are completely unexposed

(⍺).

Equation 3.1. Generalized Linear Model
𝔼𝔼〈𝑦𝑦〉 = 𝑔𝑔−1 (𝛼𝛼 + 𝛽𝛽0 𝑧𝑧 + 𝛽𝛽𝛽𝛽)

We further examined the form of the relationship of ADRD risk to cumulative
PIM exposure by coding total standardized doses as a categorical variable with
reference values of either no exposure or ≤ 25 standardized doses of exposure, in
separate regressions.
Because we expect our outcome (ADRD) to be relatively rare, we calculate
the E-value189 for new-never PIM exposure and linear cumulative PIM exposure
as a sensitivity analysis to determine whether our results might be influenced by
confounding. The E-value is a type of sensitivity analysis that calculates the
minimum strength of association that a theoretical confounder would need to have
with both the exposure and outcome in order to completely explain the observed
association. If it is plausible that there is an unmeasured confounder associated
with both PIM use and ADRD by the E-value, then this would be evidence that the
estimated effect may be confounded.

3.4.3 Results
3.4.3.1 Baseline Characteristics
The raw data provided from CMS included information on 1,645,058 unique
beneficiaries, 634,238 of whom were ultimately included in the study (see Figure
3.4.2). Beneficiaries were on average 72 years old when they entered the study,
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and about 54% were female. Cog-Beers PIM nonusers had a median (IQR) of 3
(1-6) chronic conditions, compared to PIM users who had 5 (3-8). Consistent with
this finding, beneficiaries who were new users of Cog-Beers PIMs had higher rates
of all comorbidities that may potentially confound the relationship between PIM use
and ADRD, with the most striking differences in the prevalence of anxiety and
depression.
3.4.3.2 Cog-Beers PIM Use
32.7% of the study sample were identified as new users at some point during
follow-up. The median (IQR) CSDs of PIMs among new users was 70.8 (25-296.7)
after truncating the top 1% at 4,171 CSDs. While 51/93 (54.8%) of medications
classified as Cog-Beers PIMs are strongly anticholinergic according to the 2012
Beers Criteria, only 36.9% of Cog-Beers PIMs used by beneficiaries in this study
were anticholinergic (see Table 3.4.2). The most commonly used PIM medication
class was benzodiazepines (34.7%) followed by non-benzodiazepine hypnotics
(15.1%), and antidepressants (12.7%).
3.4.3.3 Hazard of ADRD Diagnosis
The median (IQR) follow-up time in this study was 45 (23-57) 28-day periods, and
43,983 (6.93%) of beneficiaries were diagnosed with ADRD. 7.4% were censored
due to death, 1.7% were censored due to end of enrollment, and 83.9% were
administratively censored at the end of the data on 12/31/16.
In the first model of Cog-Beers PIM use on ADRD hazard, at any particular
time between 2012-2016, 1.228 times as many Cog-Beers PIM new users were
being diagnosed with ADRD compared to PIM nonusers (95% CI 1.200-12.56; see
Table 3.4.3). Adding a linear term for cumulative exposure to PIMs changes the
hazard ratio associated with new use of PIMs to 1.211 [1.183-1.241], and
estimates each increase of 100 CSDs among PIM new users increased the hazard
rate of ADRD diagnosis by 0.5% (HR [95% CI] 1.005 [1.002-1.007]). While the
association between increasing PIM CSDs and ADRD hazard rate is statistically
significant, there is significant overlap amongst groups of PIM users at various
CSDs (see Figure 3.4.3). The E-value for new-versus-never PIM use is 1.72 (95%
102

CI 1.65-1.79), and 1.08 (1.05-1.09) for the linear term measuring cumulative PIM
exposure.
When we modeled cumulative Cog-Beers PIM use categorically with
unexposed person-time intervals as the reference group, new PIM users with ≤25
SDDs have 1.209 times the rate of ADRD diagnoses (HR [95% CI] 1.209 [1.1641.256]; see Table 3.4.4) compared to non-using beneficiaries, but all PIM users
have at least 1.144 times the hazard of ADRD diagnosis. However, when the
reference group was new PIM users with ≤ 25 CSDs, the hazard for ADRD
diagnosis is only statistically significantly different at CSDs > 100. The E-value for
PIM use at > 200 CSDs is 1.54 (1.36-1.72).

3.4.4 Discussion
In this study, we examined the nature of the relationship between rate of ADRD
diagnosis and use of medications considered potentially inappropriate for older
adults with cognitive impairment or dementia according to the 2012 Beers Criteria
in a population of older adults with stand-alone Medicare Part D prescription
medication coverage.
We found that new use of Cog-Beers PIMs is associated with approximately
1.2 times the rate of incident ADRD diagnoses compared to no use of Cog-Beers
PIMs. This finding was fairly consistent regardless of the modeling technique used
to estimate it. While there are no published studies investigating the association
between PIMs when defined as medications considered potentially inappropriate
for individuals with cognitive impairment or dementia according to the 2012 Beers
criteria, other studies with similar definitions have shown similar effect sizes.64,190
In addition to using a PIM use definition that is targeted to cognitive
outcomes, this study also investigated the effect of PIM dose on rate of incident
ADRD diagnosis. We found that among new users of Cog-Beers PIMs, the rate of
ADRD diagnosis increased by 0.5% for each 100 CSDs. For reference, 100 CSDs
amounts to using the minimum effective daily dose of one PIM for 100 days.
Similarly, 100 CSDs is also equivalent to using twice the minimum effective daily
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dose of one PIM for 50 days, or of two PIMs for 25 days. In 2011, the national
average annual incidence of Alzheimer's disease alone was 0.4% among those
65-74 years old, and 3.2% among those 75-84 years old.191 Thus, an increased
rate of ADRD diagnosis of 0.5% per 100 CSDs amounts to 15% of the increased
rate seen over a decade of aging – not an insignificant risk.
For context, an individual who remained in the study for the median followup time (approximately 42 months), would amass approximately 1,260 CSDs if
they used 1 standardized PIM dose daily for the entire follow-up. When cumulative
PIM use was categorized, only beneficiaries who used more than 100 CSDs had
a significantly higher rate of ADRD diagnosis when compared to beneficiaries who
used PIMs, but less than 25 CSDs. Notably, the distribution of PIM CSDs among
new users was highly right-skewed, such that while the median CSDs for users
was merely 70, the mean was almost 350, and 10% of all PIM users filled at least
1,014 CSDs during follow-up. These findings suggest that high dose users may be
driving the association between PIM use and ADRD. While it is possible that some
confounding by indication still exists (high-dose PIM users have statistically, but
not clinically, significantly higher rates of ADRD than low-dose PIM users), the
consistent findings throughout our modeling techniques suggest that we were able
to control for this potential source of confounding. Our sensitivity analysis
suggested that a confounder would need to be associated with both new PIM use
and ADRD with a hazard ratio of at least 1.72 (95% CI 1.65-1.79) for new-versusnever PIM use and at least 1.08 (1.05-1.09) for cumulative PIM use, above and
beyond the measured confounders to explain away our estimate. The two
unmeasured confounders according to our DAG (see Figure 3.4.1) are insomnia
and Parkinson's disease, both of which have the potential to meet these criteria.
Thus, it is important that further studies be undertaken to capture the true potential
for confounding.
In addition to the consistency of our findings and the support for a doseresponse relationship, the long follow-up in this study adds to its strength. While
we restricted to beneficiaries' first continuous enrollment period, future studies
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could utilize more advanced techniques with adjustments for interval censoring to
gather additional information by allowing larger gaps between coverage.
Furthermore, while the definition of a diagnosis for ADRD in this study has
been validated,102 Medicare claims have been shown to contain both false
negative and false positive outcome misclassifications. One study estimated that
while Medicare claims that failed to identify dementia were correct in doing so 97%
of the time, the positive predictive value of dementia diagnosis in Medicare claims
was merely 0.56.192 This type of outcome misclassification could bias our results
if it is differential, which may be the case if PIMs mimic the symptoms of dementia
leading to a diagnosis without actual pathology. Future studies should link these
administrative claims to survey data with more sensitive outcome measures to
determine the true impact of potential differential misclassification.
Overall, this study highlights the importance of both exposure and outcome
definition when investigating the effect of PIM use on cognitive outcomes in older
adults. We have shown through various modeling techniques that there is likely a
dose-response relationship to the association between Cog-Beers PIM use and
rate of ADRD diagnosis in a large population of fee-for-service Medicare
beneficiaries with Medicare Part D prescription drug coverage.
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3.4.5 Tables and Figures
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Table 3.4.1. Baseline Characteristics of Medicare Population
Total
Cog-Beersa Users
Cog-Beers Nonusers
n = 634238
n = 207109
n = 427129
Demographics
Age, mean (SD)
72.31 (7.23)
72.89 (7.01)
72.02 (7.311)
Female, n (%)
344746 (54.36)
126437 (61.05)
218309 (51.11)
Nonwhite race, n (%)
67345 ()
19009 (9.18)
48336 (11.32)
b
CCW conditions, median (IQR)
4 (1-7)
5 (3-8)
3 (1-6)
Comorbidities, n (%)
Acute myocardial infarction
17375 (2.74)
6427 (3.1)
10948 (2.56)
Anxiety
44781 (7.06)
26174 (12.64)
18607 (4.36)
Atrial fibrillation
61841 (9.75)
22743 (10.98)
39098 (9.15)
Bipolar disorder
2983 (0.47)
1693 (0.82)
1290 (0.3)
Congestive heart failure
86039 (13.57)
33555 (16.2)
52484 (12.29)
Depression
80419 (12.68)
40080 (19.35)
40339 (9.44)
Diabetes
161860 (25.52)
59034 (28.5)
102826 (24.07)
Epilepsy
5018 (0.79)
2290 (1.11)
2728 (0.64)
Hyperlipidemia
392404 (61.87)
145786 (70.39)
246618 (57.74)
Hypertension
393284 (62.01)
145722 (70.36)
247562 (57.96)
Ischemic heart disease
202774 (31.97)
79499 (38.39)
123275 (28.86)
Obesity
58877 (9.28)
24556 (11.86)
34321 (8.04)
Schizophrenia
3535 (0.56)
1473 (0.71)
2062 (0.48)
Stroke
43625 (6.88)
17517 (8.46)
26108 (6.11)
Tobacco use
19412 (3.06)
8176 (3.95)
11236 (2.63)
Traumatic brain injury
2157 (0.34)
1109 (0.54)
1048 (0.25)
aM
edications listed as potentially inappropriate for older adults with dementia or cognitive impairment in 2012 Beers
Criteria; bChronic Conditions Warehouse
All group differences statistically significant at p <0.0001

Table 3.4.2. Distribution of Cog-Beers Medication Classes
Total, n (%)
Antihistamines, H1
181674 (4.39)
Antidepressants
523737 (12.65)
Antiparkinsonian agents
9478 (0.23)
Antipsychotics
241572 (5.84)
Antispasmodics
83694 (2.02)
Benzodiazepines
1435974 (34.7)
Antihistamines, H2
420735 (10.17)
Non-benzodiazepine hypnotics
624730 (15.09)
Skeletal muscle relaxants
149518 (3.61)

% Strongly anticholinergic
100
100
100
49.48
100
0
0
0
100

Table 3.4.3. Hazard of ADRD in Models with New-Never Exposure
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Model with only new-never term
Cog-Beers new vs
never exposure
Cumulative CogBeers exposure

Model with new-never
and linear cumulative terms
95% CI Bounds
p-value

HR

95% CI Bounds

p-value

HR

1.228

1.2

1.256

<0.0001

1.211

1.183

1.241

<0.0001

---

---

---

---

1.005

1.002

1.007

0.0002

All models adjusted for age, female sex, number of chronic conditions, as well as anxiety, depression, schizophrenia, and bipolar
disorder

Table 3.4.4. ADRD Hazard in Models with Categorical Cumulative Exposure
Reference: Unexposed
Reference: Person-time intervals
person-time intervals
with >0 to 25 CSDs
HR
95% CI Bounds
p-value
HR
95% CI Bounds
p-value
0 < CSDs ≤ 25
1.209
1.164
1.256
<0.0001
--------25 < CSDs ≤ 50
1.144
1.093
1.197
<0.0001
0.961
0.909
1.016
0.1588
50 < CSDs ≤ 100
1.209
1.157
1.264
<0.0001
1.018
0.964
1.076
0.5256
100 < CSDs ≤ 200
1.272
1.212
1.335
<0.0001
1.077
1.016
1.141
0.0127
200 < CSDs ≤ 400
1.333
1.268
1.402
<0.0001
1.142
1.076
1.213
<.0001
CSDs > 400
1.258
1.208
1.309
<0.0001
1.090
1.034
1.148
0.0012
Adjusted for age, sex, number of CCW conditions, anxiety, depression, schizophrenia, and bipolar disorder
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Figure 3.4.1. Directed Acyclic Graph for CMS Data
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Figure 3.4.2. Beneficiary Selection
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Figure 3.4.3. Probability of ADRD Diagnosis by Cumulative Cog-Beers Use
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3.4.6 Supplementary Data
Supplementary Table 3.4.1. Minimum Effective Daily Doses
Medication
Alprazolam
Amitriptyline
Amoxapine
Aripiprazole
Asenapine
Belladonna
Benztropine
Brexpiprazole
Brompheniramine
Carbinoxamine
Cariprazine
Carisoprodol
Chlordiazepoxide
Chlorpheniramine
Chlorpromazine
Cimetidine
Clemastine
Clidinium
Clobazam
Clomipramine
Clonazepam
Clorazepate
Clozapine
Cyclobenzaprine
Cyproheptadine
Darifenacin
Desipramine
Dexbrompheniramine
Dexchlorpheniramine
Diazepam
Dicyclomine
Dimenhydrinate
Diphenhydramine
Doxepin
Doxylamine
Estazolam
Eszopiclone
Famotidine
Fesoterodine
Flavoxate
Fluphenazine
Flurazepam
Haloperidol
Hydroxyzine
Hyoscyamine
Iloperidone
Imipramine
Lithium
Loratadine

MEDD (mg)
0.75
25
50
2
10
45
0.5
1
24
12
1.5
750
15
24
40
200
2
5
5
25
0.5
30
12.5
15
12
7.5
25
2
8
4
20
200
100
3
25
1
1
20
4
300
2.5
15
2
25
0.375
2
10
600
10

Indication
Anxiety disorders
Major depressive disorder
Major depressive disorder
Major depressive disorder
Schizophrenia
Peptic Ulcer Disease and GI Motility Disorders
Parkinsonism
Schizophrenia
Upper respiratory tract conditions
Allergies
Schizophrenia
Musculoskeletal conditions
Anxiety
Allergic symptoms, allergic rhinitis, urticaria, pruritus
Nausea and vomiting
GERD
Allergic rhinitis
Irritable bowel syndrome
Lennox-Gastaut
Obsessive-compulsive disorder
Panic disorder
Anxiety disorders
Schizophrenia
Muscle spasm
Allergic conditions
Overactive bladder
Major depressive disorder
Common cold/upper respiratory allergies
Allergy symptoms
Anxiety
Irritable bowel syndrome-associated abdominal pain
Motion sickness, nausea/vomiting, or vertigo:
Common cold symptoms
Major depressive disorder
Insomnia
Insomnia
Insomnia
GERD
Overactive bladder
Overactive bladder
Psychosis
Insomnia
Schizophrenia
Antiemetic
Gastrointestinal disorders
Schizophrenia
Major depressive disorder
Bipolar disorder
Allergic conditions
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Lorazepam
0.5
Insomnia due to anxiety or stress
Loxapine
20
Schizophrenia
Lurasidone
20
Bipolar disorder
Meclizine
25
Motion sickness
Meprobamate
1200
Anxiety
Methscopolamine
5
Peptic ulcer (adjunctive)
Molindone
50
Schizophrenia
Nizatidine
300
GERD
Nortriptyline
30
Major depressive disorder
Olanzapine
5
Schizophrenia
Orphenadrine
200
Muscle spasms
Oxazepam
30
Anxiety, mild to moderate
Oxybutynin
5
Overactive bladder
Paliperidone
6
Schizoaffective disorder
Paroxetine
10
Major depressive disorder
Paroxetine SR
12.5
Major depressive disorder
Perphenazine
8
Schizophrenia
Pimozide
0.5
Delusional infestation
Prochlorperazine
15
Nausea and vomiting
Promazine
30
Bipolar disorder
Promethazine
50
Motion sickness
Propantheline
75
Peptic ulcer
Protriptyline
15
Major depressive disorder
Quazepam
7.5
Hypnotic
Quetiapine
50
Schizophrenia
Ranitidine
150
GERD
Risperidone
2
Schizophrenia
Scopolamine
0.3
Motion sickness
Scopolamine
0.3
Motion sickness
Solifenacin
5
Overactive bladder
Thioridazine
150
Schizophrenia
Thiothixene
6
Schizophrenia
Tizanidine
2
Spasticity
Tolterodine
4
Overactive bladder
Triazolam
0.125
Insomnia
Trifluoperazine
4
Schizophrenia
Trihexyphenidyl
1
Parkinsonism
Trimipramine
50
Major depressive disorder
Triprolidine
10
Upper respiratory allergies
Trospium
20
Overactive bladder
Zaleplon
10
Insomnia
Ziprasidone
40
Schizophrenia
Zolpidem
5
Insomnia
Zolpidem SL
1.75
Insomnia
MED: minimum effective daily dose; TD: transdermal; SL: sublingual
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3.4.7 Code Blocks
Code Block 3.4.1. Models Examining Relationship between ADRD and Cog-Beers PIM Use
ods graphics on;
title "Only time-updated ever-never term";
proc phreg data = surv4;
class female (ref = "0") white (ref = "1") everexposed (ref = "0") anxi (ref = "0") dep (ref = "0") schiot (ref = "0") bipl
(ref = "0");
model (time0, time1) * censor(1) = everexposed female white age_indt anxi dep schiot bipl mcc / rl;
run;
title;
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title "Time-updated ever-never term and linear (truncated) term for cumulative exposure (in 100 standardized dose units)";
proc phreg data = surv4 plots(overlay cl)=(survival);
class female (ref = "0") white (ref = "1") everexposed (ref = "0") anxi (ref = "0") dep (ref = "0") schiot (ref = "0") bipl
(ref = "0");
model (time0, time1) * censor(1) = everexposed tsdd100_trunc female white age_indt anxi dep schiot bipl mcc /rl;
baseline covariates=covs100 / rowid=tsdd100_trunc; *generate survival curves at values specified in covs and label curves
based on tsdd_trunc value;
run; title;
title "Categorical cumulative exposure with no exposure as reference (in 100 standardized dose units)";
proc phreg data = surv4;
class female (ref = "0") white (ref = "1") tsdd100_cat0 (ref = "0") anxi (ref = "0") dep (ref = "0") schiot (ref = "0") bipl
(ref = "0");
model (time0, time1) * censor(1) = tsdd100_cat0 female white age_indt anxi dep schiot bipl mcc /rl;
run; title;
title "Categorical cumulative exposure with >0 and <= 25 SDDs as reference (in 100 standardized dose units)";
proc phreg data = surv4;
class female (ref = "0") white (ref = "1") tsdd100_cat1 (ref = "0") anxi (ref = "0") dep (ref = "0") schiot (ref = "0") bipl
(ref = "0");
model (time0, time1) * censor(1) = tsdd100_cat1 female white age_indt anxi dep schiot bipl mcc /rl;
run; title; ods graphics off;

3.5

Discussion

In this section, we have undertaken to investigate the effect of PIM use on cognitive
outcomes by utilizing different exposure definitions, outcome measurements,
study designs, statistical, and modeling techniques. We defined PIM use broadly
as use of any medication considered to be potentially inappropriate in older adults
by large consensus bodies. In addition, we applied more stringent cut-offs to these
broad criteria to eliminate confounding that may exist with incidental or nonconsistent use of PIMs, and in an attempt to quantify the effect of cumulative PIM
use. We also defined PIM use as more targeted lists of medications with more
evidence supporting their connection to cognitive decline, measuring this exposure
dichotomously, ordinally, and continuously. Finally, we calculated standardized
doses for all medications considered to be potentially inappropriate in older adults
due to negative cognitive effects and use this "Cog-Beers" PIM dose measure to
investigate a cumulative effect on rate of dementia diagnosis.
Overall, the studies in this section support the hypothesis that there is an
association between PIM use and cognitive decline, but that the way in which PIM
use is defined can have vast impact on effect sizes and significance. While none
of the estimated effect sizes were grand, many were clinically significant –
especially when targeted PIM use definitions were employed.
In addition to the varied PIM use definitions, each study measured the
cognitive outcome on a different scale. In the first study, we considered any
diagnosis of dementia as well as receipt of memory-enhancing drugs as a proxy
for clinically significant cognitive decline, which bypassed the potentially
confounding due to missed diagnoses in administrative medical claims. The
second study used a more "fine" measure of cognitive decline, the CDR-SOB,
which can capture small, sometimes clinically insignificant changes in cognition. In
addition to the short follow-up time of this study, the granular outcome may have
led one to hypothesize that no effect would be found. Nevertheless, when PIM use
was defined using targeted criteria, a clinically meaningful increase in cognitive
decline was detected. Finally, using another source of administrative claims data
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in a more generalizable population, we explored the relationship between doses
of Cog-Beers PIM use and the rate of ADRD diagnosis. Though these claims data
may suffer from the same low diagnosis rate as the first study, the strength came
from its ability to use a validated algorithm that looked through all claims over 3
years to identify an outcome.
Though all studies in this section utilized observational retrospective study
designs, their importance should not be negated. These studies are necessary to
identify a valid measure of PIM use targeted to cognitive outcomes before more
expensive and rigorous randomized controlled trials can be undertaken.
Furthermore, while there are numerous published studies in the literature that
attempt to link various PIM assessment tools to cognitive outcomes (see Section
One), none of them make use of more modern statistical inference techniques
known as causal inference. In this section, we have presented rigorously designed
investigations in order to remove a large amount of confounding and bias that is
present in the available literature. These investigations have highlighted the
importance of a consistent PIM use measurement in the context of cognitive
decline, and have shown that broad PIM criteria do not adequately capture a risk
that a large body of evidence suggests is present. Nevertheless, it appears that
these broad tools can be adapted to target cognitive outcomes, which bodes well
for their use in clinical practice.
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4

IMPLICATIONS AND RECOMMENDATIONS

4.1

Introduction

Today, adults over the age of 65 represent approximately 16% of the United States
population.26 This is nearly double what this cohort represented a mere 70 years
ago, when chronic diseases overtook acute infections as the leading causes of
death. As our society ages, medical problems unique to older adults become of
higher priority and clinicians, patients, researchers, and policy makers must strive
to stay abreast of the ever-evolving knowledge base. Specifically, as multimorbidity
and polypharmacy have risen substantially among older adults, the negative health
outcomes of potentially inappropriate medication use have reared significant
economical and societal consequences.193,194 Increasing evidence supports the
hypothesis that certain medications can have detrimental but preventable adverse
effects on mortality, functioning, hospitalization, and cognition. Because dementia
is now the fifth leading cause of death among older adults and it continues to lack
an effective treatment or cure, it is imperative that we do all that we can do prevent
what should be beneficial medication therapy from needlessly negatively impacting
cognition.
This area is of concern not only for the clinicians who struggle to optimize
often complex medication regimens, but also for their patients who generally lack
public access to information on medications that may be potentially inappropriate.
However, even if clinicians and their patients do their utmost to maintain current
knowledge on the medications that may be increasing cognitive decline, it will be
nearly impossible for them to effectively synthesize and apply this knowledge if
researchers continue to use unvalidated and inconsistent PIM assessment tools.
Without a clear consensus on how to measure PIM use to target cognitive
outcomes, systematic reviews will continue to conclude that "more evidence is
needed," and the needle will continue to stay where it is. Of course, in order to
perform this vital research task, investigators need support from their institutions
and government leaders. As we have shown in the first section of this work,
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implementation of national and local initiatives and funding to investigate ways to
reduce PIM use can have sweeping positive effects.
All stakeholders in this important area have a role to play in furthering the
study of how PIM use is impacting cognition in older adults. Before further research
can be undertaken, we must pause to clearly define the exposure of interest, or
our progress may never bear fruit.
4.2

Using potentially inappropriate medication tools in clinical practice

Optimal medical management of multimorbid complex older adult patients is no
small task. Medical providers have continually remarked that their work is so
multifaceted that key elements are often missed, such as effectively
communicating important information about newly prescribed medications.195
While it may be true that there is no single "right answer" when it comes to ensuring
a medication regimen is appropriate,22 providing clinicians with simple, validated
tools that accurately address their most pressing concerns can alleviate some of
the burden associated with taking a holistic approach to medication management.
Though the advent of broad medication appropriateness tools such as
Beers and STOPP criteria at the turn of the 21st century was a step in the right
direction, these tools are not designed to target specific health outcomes, nor to
engage patients in their medical decisions. Both of these factors are essential if
clinicians want to address potentially inappropriate medication use and intervene
to reduce its negative impact on cognition. Indeed, studies have shown that when
patients are active members of their healthcare team, are given options and
explanations as to why interventions must be made, uptake is more successful.196–
198

One approach to aid in reducing PIM use in older adults by more actively

engaging patients is to adopt a team-based approach to medication management.
Pharmacists, whether present at the medical clinic, hospital, or community, can
play an integral role in withdrawing or changing inappropriate medications as
foremost medication expert in healthcare.199–201 In addition to providing more
patient-clinician facetime, Pharmacists can also reduce the workload of
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prescribers by taking responsibility for utilizing medication appropriateness
assessment tools.
Regardless of the structure of clinician-patient relationships and who
participates as members of the team, this work supports the adoption of targeted
PIM use measures when deprescribing in the context of cognitive decline and
impairment. This work has shown that new tools need not be developed. Rather,
existing sub-lists in already well-known and respected criteria can be used as a
starting point to address PIM use. As the Beers Criteria are the most commonly
used explicit criteria in the United States, the findings in this work support the
adoption of the Cog-Beers PIM measure to target assessment of medications for
cognitive outcomes. While the strongest link between these medications and
cognitive decline exists among patients who already experience cognitive
impairment, this work has shown that there is a significant effect of Cog-Beers PIM
use on cognitive decline, even amongst those cognitively normal at baseline. After
exploring various other measures of PIM use, this work was not able to find one
tool that was meaningfully better-associated with cognitive outcomes than any
other. Thus, in the case when a clinician is more comfortable using another PIM
assessment tool, we recommend using targeted components of general tools or
PIM assessment tools that contain only medication specific to the cognitive
context.

4.3

Measuring potentially inappropriate medication use in research

In the thirty years since geriatrician Mark Beers first developed what is known
today as the "Beers Criteria," the field of medication appropriateness has grown
substantially. As a benchmark for how much research has been produced in the
area, there have been at least 13 reviews published in the last eight years covering
potentially inappropriate medication use in older adults.16,20,38,105,172,202–209 This
flourishing field has led to the development of over forty tools meant to assess
various aspects of medication appropriateness. As we have shown in section one,
however, only six of these have been used in studies investigating the link of PIM
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use as defined with the criteria to cognitive outcomes. While there are certainly
other important health outcomes that other PIM assessment tools may address,
given the burden of cognitive disease in today's society, it is striking that so few
tools have been validated.
This work has investigated only some of these tools – from the most broad
to the most specific – to determine whether any was substantially better at
predicting cognitive decline when used to measure PIM use in older adults. After
review of various definitions of polypharmacy, various applications of the complete
2012 and 2015 Beers Criteria and version 2 of the STOPP criteria, and cumulative
use of medications in sub-lists from both aforementioned tools that include only
medications supposed to have cognitive effects, this work has not determined that
any of the studied tools is meaningfully better at predicting cognitive decline.
Nevertheless, we were able to clearly demonstrate that targeted lists of PIMs such
as the Cog-Beers list are more highly associated with cognitive declines and that
the relationship between diagnosed ADRD and use of these PIMs may be dosedependent.
Based on these findings, we recommend that other investigators continue the
work of validating medication appropriateness tools for their association with
cognitive outcomes, with the ultimate goal of reaching a consensus tool that should
be used in all future research endeavors that investigate the effect that using these
PIMs has on cognitive decline. Should this goal be achieved, more randomized
and controlled trials can be undertaken to answer the next most important question
of whether reducing use of PIMs can actually prevent or slow the development of
cognitive decline. Without first establishing a clear and universal definition for CogPIM use, it will be difficult to lead the field forward and make meaningful differences
in patients' lives.

4.4

Championing appropriate medication use in society

For the last two decades, governments around the world have recognized that
inappropriate medication use in older adults is a critical public health concern, and
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have taken steps to implement initiatives and provide funding to alleviate this
problem. These steps have made remarkable progress, leading to such feats as
the cross-national SIMPATHY project in the European Union,24 and the "Quality
Use of Medicines" national strategic initiative in Australia.23 However, governments
and other large public and private institutions should also consider that medication
appropriateness in older adults crosses into the domain of cognitive health quite
clearly, and take the opportunity to provide greater access to funding and
resources for this important intersection. For example, because Alzheimer's
disease is one of the most expensive chronic conditions in the United States, the
government has provided special access to increased funding for research into
this important condition.210 However, there are no nationally sponsored funding
opportunity announcements for research into the effect of potentially inappropriate
medication use of Alzheimer's dementia or any other cognitive disorder.211 The
closest call for research would be classified as a "non-pharmacological
interventions," which covers is a wide pool of potential research areas.
This work supports the expansion of available federal and private resources
to investigate the impact PIM use has on cognitive outcomes. The first step may
be to make available funds for observational work that strives to link a PIM
assessment tool to clinically relevant cognitive outcomes, and for further validation
studies of that tool in a variety of data sources. Once researchers have taken
advantage of this funding and produced evidence, more calls for clinical trials
investigating the effect of PIM use reduction on cognitive preservation can be
released. Evidence provided herein has demonstrated that the current state of the
field of PIM use and cognitive decline is not yet ready to blossom into widespread
uptake in the cognitive research community. However, with the proper funding and
incentives, governments an large institutions can push forward the work in this
important area. Whether it leads to expanded clinical trials into a heretofore underresearched area or leads to the conclusion that reducing PIM use may not be a
clinically effective strategy to mitigate cognitive decline, we will never know until
we are given the opportunity to investigate.
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"If we knew what we were doing, it would not be called research, would it?"
- Albert Einstein
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10th Annual Therapeutics, Outcomes, Discovery, and Delivery
Symposium

October 2019

Best Spotlight Poster Presentation
International Conference for Pharmacoepidemiology and
Therapeutic Risk Management

August 2019

Pharmaceutical Sciences Excellence
Achievement Fellowship
University of Kentucky College of Pharmacy

in

Graduate

Women and Philanthropy Travel Scholarship
Sanders-Brown Center on Aging, University of Kentucky Women
and Philanthropy Network
Outstanding Poster Award
Markesbery Symposium on Aging and Dementia

2019-2020

May 2019

October 2018

Second Place Winner, Elevator Speech Competition
September 2018
9th Annual Therapeutics, Outcomes, Discovery, and Delivery
Symposium
Scholarship, Annual Meeting
International Conference for Pharmacoepidemiology and
Therapeutic Risk Management

August 2018

Registration and Travel Scholarship, Midyear Meeting
International Society for Pharmacoepidemiology

April 2018

Dean’s List
University of Kentucky College of Pharmacy

May 2016

1st Place Poster Presentation, Pharmacy Student Division
Rho Chi Alpha Xi Chapter at the University of Kentucky
College of Pharmacy

March 2016

National Patient Counseling Competition Local Chapter
Winner
American Pharmacists Association—Academy of Student
Pharmacists

February 2016

Wrightson Memorial Scholarship
University of Kentucky College of Pharmacy

2014 – 2017

Student Enhancement Scholarship
University of Kentucky College of Pharmacy

2013 – 2017
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